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Abstract
End-stage renal disease (ESRD) is increasingly a problem in the United States, and
factors such as race/ethnicity and gender may not only worsen the risk of the disease but
also correspond to worse treatment access. This is significant because ESRD is a heavy
economic burden not only on patients, but on caregivers and the health care system,
especially as disparities remain between different demographic groups. The purpose of
this quantitative nonexperimental, historical, correlational design was to determine the
extent to which gender and race/ethnicity predict 30-day readmission rates after
hospitalization for ESRD patients. The theoretical framework for the current study was
the theory of the determinants of avoidable readmissions in ESRD. The three research
questions were to what extent patient gender predicts 30-day hospital readmission rate for
ESRD patients, to what extent does patient race/ethnicity predicts 30-day hospital
readmission rates, and are there any significant interactions terms in a combined
prediction model using gender and race/ethnicity. Data were gathered from Data.gov and
the United States Renal Data System. Regression analysis was used to analyze the data.
The study found that gender, race, and income can all be predictors of ESRD
hospitalization. The results have important implications for improving interventions to
reduce ESRD hospitalization, thereby leading to positive social change by reducing both
the personal and societal costs associated with the disease.
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Section 1: Foundation of the Study and Literature Review
Introduction
End-stage renal disease (ESRD) is a serious problem today, affecting over two
million people worldwide (Robinson et al., 2016). Although the condition has nearly
plateaued in the developed world, the incidence is still slowly increasing. The United
States alone sees over 120,000 new cases annually (Saran et al., 2017). ESRD is the fifth
and final stage of chronic renal, or kidney, disease, at which point a patient’s kidneys
have failed entirely. Treatment at this stage requires hemodialysis, an external filtration
device that filters the patient’s blood in place of the kidney. The only cure for ESRD is a
kidney transplant, and, at present, there is a significant disparity between availability and
demand (Robinson et al., 2016). This disparity is especially present for minorities, even
in developed countries. Of all chronic conditions, including cancer and heart disease,
ESRD is the most likely to result in hospitalization (Lovasik et al., 2016). Unnecessary
ESRD-related hospitalizations impose a high cost and represent the best way to
simultaneously decrease ESRD costs and improve treatment (Matthew et al., 2015).
The purpose of this quantitative nonexperimental, historical, and correlational
design was to determine the extent to which gender and race/ethnicity predict 30-day
readmission rates after hospitalization for ESRD patients. The study also examined
interactions between these variables on the overall risk of ESRD-related hospitalization.
The sample population was all adults with ESRD in the United States. The key variables
were gender and race/ethnicity, 30-day readmission rates, and ESRD-related
hospitalization risk.
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Problem Statement
ESRD is increasingly a problem in the United States, with over 120,000 new
cases in 2014 alone and over 660,000 total cases in treatment (Saran et al., 2017). The
specific problem is that factors such as race/ethnicity and gender may worsen the risk of
the disease (Crews et al., 2018) and correspond to worse treatment access (Patzer et al.,
2015). While ESRD diagnoses are increasing in general, the problem is that minorities,
especially minority women, may be at high risk for poor outcomes. This problem is
significant because ESRD is a heavy economic burden on patients, caregivers, and
society (Wang et al., 2016). While mortality rates associated with the condition have
declined in the past 2 decades (Collins et al., 2015), considerable disparities remain
between different demographic groups, and for minority groups, these benefits have been
less pronounced (Robinson et al., 2016).
The predictors of ESRD are nuanced and may not also be appropriate for
traditional modeling. For example, dividing patients into two age brackets of those above
65 or 80, a common cutoff in medical research, provides an inaccurate depiction of
ESRD risks (Krishnaswami et al., 2016). Additionally, many of the factors predicting
worse than average ESRD outcomes may be psychosocial, such as Blacks having a lower
rate of treatment compliance strongly associated with experiencing everyday racism
(Savage, 2017). Additional research is needed to help ease the economic burden of ESRD
by reducing readmission rates (Matthew et al., 2015). Such research will benefit from
considering socioeconomic and other contextual factors (Newman et al., 2016),
especially those that may contribute to or create race and gender disparities in treatment
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and outcomes (Shah, Leonard et al., 2018). The need to better understand the roles of
race and gender emerged as a pointed gap in the literature. Addressing this identified
research gap is important to health administration because unplanned rehospitalizations
are expensive, and the burden of that expense falls on both patients and the hospitals that
treat them. Thus, reducing readmission rates is an important outcome for both practical
and altruistic reasons.
Purpose of the Study
The purpose of this quantitative nonexperimental, historical, correlational design
was to determine the extent to which gender and race/ethnicity predict 30-day
readmission rates after hospitalization for ESRD patients. The study also examined
interactions between these predictors on the overall risk of ESRD-related hospitalization.
Thus, the independent variables were gender and race/ethnicity. Additionally, the
dependent variables were 30-day readmission rates and ESRD-related hospitalization
risk, respectively. I gathered the data from two different historical databases: the USRDS
for the first set and Data.gov for the second. These data were readily and publicly
available, allowing me to easily access them and then perform multiple regression and
ANOVA analyses. The large, national datasets available ensure that meeting the
minimum sample size requirements were easily achieved and exceeded.
Research Questions and Hypotheses
The following quantitative research questions guided the current study. For each
research question, a null and alternative hypothesis was presented.
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RQ1: To what extent, if at all, does patient gender predict 30-day hospital
readmission rate for ESRD patients in the United States?
H01: Patient gender does not predict 30-day hospital readmission rate for
ESRD patients in the United States.
H11: Patient gender predicts 30-day hospital readmission rate for ESRD
patients in the United States to a statistically significant degree.
RQ2: To what extent, if at all, does patient race/ethnicity predict 30-day hospital
readmission rate for ESRD patients in the United States?
H02: Patient race/ethnicity does not predict 30-day hospital readmission rate
for ESRD patients in the United States.
H12: Patient race/ethnicity predicts 30-day hospital readmission rate for ESRD
patients in the United States to a statistically significant degree.
RQ3: Is there a significant interaction between gender and race/ethnicity in
predicting 30-day hospital readmission rate for ESRD patients in the United
States?
H03: There is not a significant interaction between gender and race/ethnicity
in predicting 30-day hospital readmission rate for ESRD patients in the United
States?
H13: There is a significant interaction between gender and race/ethnicity in
predicting 30-day hospital readmission rate for ESRD patients in the United
States?
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Theoretical Foundations
The current study's theoretical framework was the theory of the determinants of
avoidable readmissions in ESRD proposed by Matthew et al. (2015). This theory
characterizes the aspects contributing to avoidable hospital readmissions for ESRD
patients and presents such factors as characteristics of the patient’s hospital stays, the
hospital itself, the dialysis facility, the nephrologist and other care providers, and the
existing payment structure. The current study drew on one specific aspect of this theory,
focusing on the role of patient characteristics. However, the various determinants of
avoidable readmission have complex interrelationships with one another (Matthew et al.,
2015). Therefore, a detailed understanding of this specific and perhaps foundational
determinant of avoidable readmissions is important in further testing and developing this
theory. Also, the theory’s proposition that many ESRD-related readmissions following
hospitalizations are avoidable from a health administration standpoint represents one of
the driving forces behind the current study. By identifying the causes of avoidable
rehospitalizations, they may be better targeted with interventions to reduce them,
benefitting both patients and hospitals.
Nature of the Study
The nature of the current study was that of a quantitative, historical, correlational
design. Quantitative research is an approach that examines the world from a numerical,
objective perspective (Bryman, 2016). Quantitative research is useful for examining
issues that can be quantified, such as those for which there are existing, validated
quantitative instruments to measure, or for understanding the nature of the relationships
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between two or more variables (Bryman, 2016). Overall, the greatest benefit of a
quantitative study is that the results are based solely on objective data measured using
carefully validated instrumentation. The numerical or otherwise closed-ended nature of
this type of data also means that quantitative research can practically process and analyze
large sample sizes (Bryman, 2016). Because it uses larger sample sizes, quantitative
research creates results that can be generalized, strengthened, and measured using
statistical techniques, such as power analyses and confidence intervals. All of this made
the quantitative approach a strong fit for the current study because I sought to examine
the relationships between easily quantified and measured variables. All the predictor and
outcome variables in the research questions—gender, race/ethnicity, and 30-day hospital
readmission rate—were either quantitative by nature or easily assessed sociodemographic
variables. Furthermore, all three of the research questions guiding the current study
pertained to the nature of the relationship(s) between these variables, and, as the next
section demonstrates, large datasets are available containing these data.
Data for the study was drawn from two secondary sources: Data.gov and the U.S.
Renal Data System (USRDS). Data for RQ1 to RQ3 were drawn from the dataset
available through the USRDS. Therefore, for the present study I requested the use of data
for the 2016-2018 period for Medicare patients. The relevant dependent variables were
hospitalization and 30-day readmission, whereas the independent variables were
race/ethnicity and gender. All these variables are available in the Medicare dataset as per
the USRDS website. The USRDS does not, however, include preferred language data.
Therefore, for this purpose, a dataset from Data.gov was utilized that contained data on
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the preferred language of Medicare claimants for ERSD on an annual basis since 2016.
From this dataset, I collected the dependent variable of hospitalization.
Literature Review Search Strategy
The purpose of this quantitative nonexperimental, historical, correlational design
was to determine the extent to which gender and race/ethnicity predict 30-day
readmission rates after hospitalization for ESRD patients. The study also examined
interactions between these predictors on the overall risk of ESRD-related hospitalization.
The following research questions guided the study:
RQ1: To what extent, if at all, does patient gender predict 30-day hospital
readmission rate for ESRD patients in the United States?
RQ2: To what extent, if at all, does patient race/ethnicity predict 30-day hospital
readmission rate for ESRD patients in the United States?
RQ3: Are there any significant interaction impact between gender and
race/ethnicity in predicting 30-day hospital readmission rate for ESRD patients in
the United States?
I reviewed the academic and medical literature to inform the study in answering these
research questions.
I carried out this literature search using Walden University Libraries. I used
PubMed, Medline, and Google Scholar. Keywords utilized in the literature search
included renal, kidney, hospitalization, demographic, ESRD, end stage renal disease,
race, ethnicity, language barrier, epistemological triad, and appropriate combinations.
After carrying out these searches, I examined the titles in the results. Based on the titles
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that seemed relevant, I narrowed the literature search and reviewed the abstracts of those
articles with promising titles. Based on this review of the abstracts, I ultimately selected
the most relevant articles. All of these articles were recent sources from within the past 5
years (2015-2019). All the sources chosen were from peer-reviewed scholarly journals,
scholarly books, or dissertations.
I divided the resulting literature into themes that served to support the study. The
literature review begins with a more in-depth look at the theoretical framework for the
study. Five key themes follow this theoretical framework. First is the significance of
ESRD as a problem. Second, are the complications and comorbidities of ESRD. Third,
are the treatments of ESRD. Fourth is ESRD and hospitalization. The fifth and final
theme is ESRD and demographics. I also evaluated the importance of the key variables in
this study. The independent variables were gender and race/ethnicity, whereas the
dependent variables were 30-day readmission rates and ESRD-related hospitalization
risk.
Literature Review Related to Key Variables and Concepts
Thus, the independent variables were gender and race/ethnicity. The dependent
variables were 30-day readmission rates and ESRD-related hospitalization risk.
Theoretical Framework
The theoretical framework for the current study was the theory of the
determinants of avoidable readmissions in ESRD proposed by Matthew et al. (2015). As
will be further emphasized in the later section on ESRD and hospitalization, ESRDrelated hospitalizations, like all hospitalizations, are costly for both the patient and the
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hospital. Overall, unnecessary hospitalization has a high societal cost and should be
avoided where possible (Matthew et al., 2015). Some hospitalizations, especially for a
chronic condition like renal disease, are not avoidable. However, many hospital
readmissions are avoidable. Understanding the differences between avoidable and
unavoidable hospitalizations and especially readmissions is a key idea in reducing the
societal and individual costs of ESRD. As many ESRD patients are on Medicare for their
treatment (Mu et al., 2018), these costs are far-reaching and significant.
Matthew et al. (2015) sought to develop a framework that characterizes the
aspects of treatment and its circumstances that define or contribute to avoidable hospital
readmissions for ESRD patients. As per the theory, such relevant factors have significant
breadth, including characteristics of both the patient’s hospital stay and the hospital itself,
the dialysis facility, the nephrologist and other care providers, and the existing payment
structure. The current study does not examine all these factors; instead, it is focused on
one of the framework’s relevant dimensions: patient characteristics. As per Matthew et al.
(2015), patient characteristics are far from the only factor that may drive avoidable,
ESRD-related readmissions for patients, but they do represent one highly important set of
factors. As per the theory, all these determinants of readmission are interrelated;
therefore, studying even this single aspect may shed some light on broader issues.
In particular, the patient characteristics and factors in this study may be deeply
interrelated with treatment characteristics. As discussed later in the demographics section,
many patient characteristics may affect both care quality and the places from which care
is received, in addition to the likelihood of facing ESRD in the first place (Newman et al.,
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2016). Therefore, through Matthew et al.’s (2015) theory, the narrower results in the
present study may link to the broader spectrum of issues causing ESRD hospitalization
and avoidable readmissions. In practical terms, avoidable readmissions usually indicate
either a failure of treatment on the part of the healthcare provider or a failure on the part
of the patient to adhere to posttreatment self-care. Both factors can be avoided, but
because of the interconnectedness, failure of treatment can also be related to patient
characteristics, not merely to provider and care characteristics. For example, as per
Savage (2017), if patients perceive bias or racism from their healthcare provider, they
may be less likely to comply with posttreatment care directions, whereas that same tacit
bias can also cause providers to offer poorer care (Phelan et al., 2015).
Overall, therefore the Matthew et al. (2015) theory was the foundation of the
current study. It provided not only a strong theoretical justification for the current study’s
focus on patient characteristics but also suggested a broader theoretical context into
which the current study fits. The current study does not exist in a vacuum, and the
variables under consideration could likely never serve to characterize the problem
entirely. By adopting a theoretical foundation that shows how those factors are related to
other key determinants of avoidable rehospitalization, I contextualize the current study in
the broader theoretical landscape. Furthermore, this theoretical grounding suggests the
key outcome variable, that of ESRD-related 30-day rehospitalization, a choice that will
be further supported by the later section that focuses on hospitalization specifically.
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Significance of End-Stage Renal Disease
ESRD is the final stage of a broader condition known as renal disease, kidney
disease, or nephropathy (Cobo et al., 2016). Renal disease can be characterized broadly
as either nephritis, which is inflammatory kidney disease, or nephrosis or
noninflammatory kidney disease (Cobo et al., 2016). Regardless of whether a specific
kind of renal disease is inflammatory or not, the ultimate effect is damage to the kidneys
and the impediment of their health function. Chronic or long-term kidney disease
progresses gradually, starting with no symptoms and developing significant symptoms
over an extended period (Cobo et al., 2016); it is a chronic kidney disease that is
generally under consideration in the case of ESRD.
The human kidney’s main function in vertebrates as a whole is blood filtration
(Krolewski et al., 2017). The kidney filters the bloodstream, catching waste and diverting
it to the urinary tract to be expelled in urine. Accordingly, impaired kidney function is
problematic because it prevents waste from being properly removed from the
bloodstream, allowing it to build up to dangerous levels (Krolewski et al., 2017). Renal
disease prevents or limits excess liquid expulsion from the body, marking significant
kidney damage as quite dangerous. A precise medical definition of renal disease is
somewhat more complicated and specific. As per Webster et al. (2017), the exact
definition of the condition has changed and evolved, but the currently accepted
international definition is “decreased kidney function shown by glomerular filtration rate
(GFR) of less than 60 mL/min per 1·73 m2, or markers of kidney damage, or both, of at
least 3 months duration, regardless of the underlying cause” (p. 1238). However, the most
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common causes are diabetes and hypertension, though the leading causes also differ
across differing contexts, such as in different ethnic groups (Webster et al., 2017).
In the context of chronic renal disease, the end-stage is defined as the point at
which natural kidney function has ceased mostly or entirely and must be partially or
entirely replaced by external hemodialysis (Robinson et al., 2016). Hemodialysis, or
dialysis, is a process in which a person’s blood is cycled through an external device,
which replaces the kidney’s filtration function (Robinson et al., 2016). At this point,
ESRD is a condition of extreme concern, especially in a worldwide context. ESRD
affects over two million people worldwide, and it may have significant mortality in the
global setting (Robinson et al., 2016). The specific mortality rates resulting from ESRD
differ heavily based on the type of care available in a region and the population’s access
to that care. In general, ESRD treatment with in-center hemodialysis is associated with a
poor survival rate overall, though this is higher/longer in some Asian countries and parts
of Europe (Robinson et al., 2016). Furthermore, ESRD poses the greatest risk of
mortality soon after its onset, suggesting that those patients at this point fail to gain
access to dialysis or to adjust their lifestyles to accommodate the need for it (Robinson et
al., 2016).
In the United States, renal disease is classified into five stages. Counting all these
stages, about 15% (14.8%) of the United States population has chronic renal disease, with
most of these being at stage three (Robinson, 2016). Even in the United States, ESRD
testing is lower than ideal, with less than half (48%) of the population, even within
Medicare participants, being properly screened for the condition. Even so, ESRD
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incidence and diagnosis is increasing, with 120,688 new diagnoses in 2016, a 1.1%
increase from 2015. Overall, ESRD rates are increasing at a faster rate, of 3.5% from
2013 to 2014, with 678,383 total cases in 2014; however, this is somewhat encouraging
because it suggests that there have also been significant decreases in ESRD mortality
from better treatment. Indeed, relative to the rest of the world, the United States rates of
ESRD are improving. Although they continue to rise, 1% is a relatively small growth.
Thus, in affluent countries such as the United States and Japan, ESRD rates are
stabilizing, relatively speaking (Wetmore & Collins, 2016). However, in poorer or
otherwise developing countries, healthcare systems struggle with soaring rates of renal
disease. These soaring rates of ESRD also contribute to a widening gap between the
number of ESRD patients who can receive kidney transplants, the only effective cure,
and the number of available kidneys (Wetmore & Collins, 2016). In terms of the causes,
research supports that diabetes is the most common cause. Burrows et al. (2017) further
attested to roughly 120,000 new cases of ESRD annually in the United States, and their
analysis suggested that “among these persons, 44% (approximately 53,000 persons) had
diabetes listed as the primary cause of ESRD (ESRD-D)” (p. 1165). Interestingly,
however, the role of diabetes as a cause of ESRD has changed over time. Based on a
retrospective analysis of ESRD data for the period 2000-2014, the incidence of diabetesrelated ESRD has decreased by about 33% (Burrows et al., 2017). This is an interesting
shift and suggestive of either better control of the complications of diabetes or a more
significant rise in other causes of ESRD.
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Regardless of its cause, however, ESRD is significantly problematic. There are
significant burdens associated with the condition, perhaps the foremost of which is
financial. Indeed, ESRD creates high costs for multiple stakeholders, including patients,
caregivers, and society (Wang et al., 2016). The growing trend in chronic kidney disease
has made these economic concerns more important because they call into question the
present capacity to manage these costs. This is especially true because the numbers of
those struggling with ESRD are growing at both ends, with both an increase in diagnoses
and an increased survival chance. ESRD is especially costly because the costs associated
with the condition increase throughout disease progression, yet most research shows only
the tip of the proverbial iceberg in that it looks at only direct costs of care (Wang et al.,
2016). Thus, the true extent of the cost of ESRD when indirect expenses are factored in is
unknown. Indeed, only recently have new analysis techniques that are suited to large
datasets been applied to ESRD data. As per Liao et al. (2016), cluster analysis is a data
analysis technique that has been used to successfully analyze data in several fields, but
rarely in healthcare data.
The Liao et al. (2016) study was an exploratory attempt to apply this analysis
technique to a relatively small cohort (roughly 19,000 patients) as a proof of concept for
cluster analysis and k-mean grouping in medical expenses, ESRD. Their results
suggested that expenses following the commencement of dialysis treatment are relatively
stable in patients with a low number of comorbidities. In contrast, the researchers
associated a high number of comorbidities with more unpredictable and often increasing
costs following the beginning of dialysis (Liao et al., 2016). While a somewhat intuitively
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obvious result, this did support the use of techniques of this sort to better understand the
costs of ESRD. Nonetheless, this supports Wang et al.’s (2016) assertion that the overall
costs of ESRD are poorly understood.
This lack of understanding of the depth of the problem may be part of the reason
for a dearth of research (Mendu et al., 2016). While significant academic research
regarding ESRD exists, as this review evinces, Mendu et al. (2016) argued that this
research is less than it could be. Specifically, they argued that as illustrated by this
section, kidney disease should be considered a significant problem in the United States
and that significant federal funding should be allocated. However, ESRD is
underrecognized as a problem relative to other health conditions and therefore receives
less research and funding than similarly prominent problems (Mendu et al., 2016). Some
strong means to conduct such research already exist, however. The most prominent of
these is the dataset that I used for the current study, the USRDS.
Collins et al. (2015) reported recently on the history and significance of this
massive dataset. The USRDS was created by the University of Minnesota in 1989. This
original database only focused on the incidence and prevalence of ESRD. However, in
2001, the Minneapolis Medical Research Foundation transformed this database into a
more comprehensive source of information that includes a wide array of related topics
such as disease severity, hospitalizations, pediatric populations, prescription drug use,
and chronic kidney disease, and the transition to ESRD. Such data represents a rich
source of data with which to conduct research. It should be noted that ESRD, in addition
to its financial costs, has high costs in terms of quality-of-life (Raspovic et al., 2017).
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Although these are more physical than mental, overall, having ESRD has been found to
represent a significant decrease in terms of quality of life even for patients already
suffering from a chronic condition such as diabetes, much less for those without one.
Overall, therefore, ESRD is a significant problem on a global scale. In developed
countries, such as the United States, ESRD incidence has plateaued in recent years,
compared to its past growth. Nonetheless, some stage of renal disease affects nearly 15%
of the United States population. ESRD can have significant consequences, including but
not limited to death, high healthcare costs, and lowered quality of life. Therefore,
research into ESRD should be a priority to determine how to best lower the still-high
incidence of this expensive and dangerous condition.
Complications and Comorbidities of End-Stage Renal Disease
As per Mendu et al. (2016), one of the decisive factors in determining the cost of
ESRD may be the comorbidities and complications it brings. Given that ESRD can be
caused by two other significant chronic conditions, hypertension and diabetes, these
diseases represent two important and dangerous comorbidities for ESRD. Diabetes is the
cause of over 40% of ESRD, and thus the two conditions co-occur in nearly half of
patients (Burrows et al., 2017). The most significant complication of ESRD is mortality.
As of 2015, ESRD was the cause of death for 1.2 million people worldwide, a drastic
increase in just 25 years; only about 400,000 died of ESRD in 1990 (Global Burden of
Disease, 2016). Kidney failure without adequate dialysis treatment leads to almost certain
death, as the body can no longer effectively filter waste out of the bloodstream. Even
under dialysis treatment, the effectiveness of the treatment versus the rate of waste
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accumulation may not be enough (Robinson et al., 2016). Furthermore, dialysis treatment
often requires access to the facility and a consistent means of transportation and the
dedication necessary to maintain a rigorous and highly time-consuming dialysis regimen.
As a result, ESRD has a high mortality rate even in developed countries, where mortality
is highest immediately following ESRD onset (Gillespie et al., 2015). Interestingly,
despite the overall greater role of diabetes causing ESRD, significantly more ESRD
deaths result from hypertension-caused ESRD (550,000 annually) than result from
diabetic ESRD annually (420,000 annually; Global Burden of Disease, 2016)
Another somewhat prominent comorbidity and one of the most important is that
of cancer. Although not nearly as common a comorbidity as diabetes, which is strongly
related as a cause of ESRD, cancer has important interactions with ESRD. Research by
Butler et al. (2015) suggested that ESRD may be a potential cause of cancer, or at least
that ESRD patients at an increased risk of cancer. Like the current study, the researchers
in this study adopted an approach using historical ESRD Medicare data to conduct a
quantitative retrospective cohort study of ESRD patients. They found that the 5-year
incidence rate of any kind of cancer following ESRD and the onset of dialysis was
9.48%. The results suggested that the incidence rates of certain common cancers
increased, but others specifically decreased. Specifically, the incidence of kidney/renal
pelvis cancer increased, while the risk of colon/rectum, lung/bronchus, and pancreas
cancers decreased following the onset of dialysis treatment. Nonetheless, the overall
association of cancer as a potential complication of ESRD is troubling, given the
considerable additional cost and danger posed by cancer.
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ESRD may be comorbid with or even a result of cancer, especially renal cancer
(Nguyen et al., 2017). One specific mechanism of note in this regard is that cancerrelated ESRD may occur following surgery to remove parts of the kidneys that are
malignant. Based on analysis of a historical dataset from 1983 to 2007, again using the
same USRDS dataset that the current study adopted, Nguyen et al. (2017) examined the
outcome of these cancer-related cases of ESRD. They found that patients with renal
cancer-related kidney removal or surgery had significantly decreased survival rates
relative to the average for ESRD. The study’s results must be examined in the context of
general cancer-related dangers, which could decrease the survival chances of those with
both ESRD and renal cancer. Nonetheless, this comorbidity was associated with a
decreased life expectancy. Interestingly, relative to diabetic ESRD, patients with ESRD
related to or resulting from kidney reduction or removal for non-cancer-related reasons
was associated with increased life expectancy.
Overall, ESRD has significant comorbidities and may be associated with
significant complications. Being as diabetes and hypertension are the main causes of
ESRD, they are also its most pronounced comorbidities. However, there are other
significant comorbidities, such as lupus erythematosus and renal cancers. Some of these
comorbidities, such as lupus erythematosus, have significantly different patterns of
occurrence based on gender, ethnicity, and other gendered factors. The most prominent
complication of ESRD is death; ESRD is a quite lethal condition if not treated promptly
and consistently. In addition, ESRD may result in other complications such as foot ulcers,
lower-extremity amputation, and renal cancer. Overall, cancer has a high incidence in the
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5 years following an ESRD diagnosis, especially renal cancer. Conversely, ESRD
resulting from renal cancer and its treatment is especially deadly.
Treatments of End-Stage Renal Disease
As noted in the previous section, prompt, and consistent treatment of ESRD is
completely necessary to avoid mortality. As ESRD represents the point of essentially
total kidney failure, the minimum treatment necessary is hemodialysis, an external,
artificial filtration process that replaces the kidneys' function. Although not as effective as
a real kidney, dialysis is a functional treatment. However, the only true cure for ESRD is
a kidney transplant (Wetmore & Collins, 2016). Unlike many other organs, kidney
transplants are relatively unique in that, because a person can function acceptably well
with a single kidney, kidney transplants need not be taken from deceased donors (Shah et
al., 2016). Instead, a living donor can give a kidney and both the donor and recipient can
function with a single kidney in place.
Nonetheless, there is a significant gap between transplant availability and
transplant demand. This gap is even broader in the developing world, as ESRD incidence
rates increase significantly faster than the rates of those receiving renal replacement
therapy (Wetmore & Collins, 2016). As with other aspects of ESRD, demographics play
a role in transplantation. Minority patients have a significantly higher presence on kidney
transplant waitlists and represent a significantly lower portion of the donor pool
(Newman et al., 2016). The reasons for these disparities are complicated and beyond the
scope of the present study, but the existence of the disparities themselves is highly
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problematic. Even in terms of simpler treatment such as dialysis, however, the existing
literature suggests several important issues.
One such result, by Gillespie et al. (2015), suggested the importance of prompt
care even more strongly. In their study, Gillespie et al. (2015) examined the relationship
between a prior history of nephrology—care by a kidney doctor—and mortality in newlydiagnosed ESRD patients. As with much other research, their study drew upon the
USRDS as a data source and included nearly half a million patients between 2006 and
2010. Their results indicated that “overall, 33% of new ESRD patients had received no
prior nephrology care, while 28% had received care for >12 months” (p. 772). The low
incidence of care prior to reaching the end stage is troubling in that it suggests patients
fail to achieve any specialized care, which might have prevented their renal disease from
advancing to stage five. However, those who had no prior nephrology care were also at
significantly higher risk of first-year mortality; conversely, pre-existing nephology
treatment was not only associated with better survival rates but a host of other positive
outcomes, including the discussion of transplantation options.
Another study, by Cervantes et al. (2018), emphasized the importance of prompt
and consistent dialysis treatment. Their study was concerned with the plight of
undocumented immigrants, who may at present only receive dialysis treatment on an
emergency basis. Their study compared the results of receiving dialysis three times a
week to receiving it on an emergency-only basis. This study also adopted a retrospective
cohort study, though a smaller-scale one that included data from only three hospitals from
2007 to 2014. As expected, the results of their analysis indicated that there was a higher
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mortality rate for those who only received dialysis on an emergency basis. However, the
magnitude of that difference was still quite striking, with 5-year mortality for those
receiving only emergency dialysis being a staggering 14 times higher. In each case, the
population was similar, being undocumented immigrants. These results strongly bear out
the importance of consistent dialysis treatment for those with ESRD and suggest that an
emergency-only treatment basis is not, in practical terms, a feasible strategy.
Another issue of interest is blood pressure control during treatment. Given that
hypertension is the most lethal cause of ESRD, blood pressure control during dialysis has
traditionally been a tenet of ESRD treatment (Ku et al., 2015). However, this guideline
has been an issue of some contention amongst doctors because randomized control trials
have, thus far, failed to demonstrate significant effects, but strict blood pressure control
during this period could have more tacit implications in the long term. Accordingly, to
examine this, Ku et al. (2015) used the USRDS to follow up on patients from a 19891993 study of renal disease and blood pressure control. Although the original study had
failed to show any significant effect of blood pressure control on renal disease
progression, the follow-up study found that there was a significant reduction to long-term
mortality risk, with a roughly 25% lower risk of mortality in the strict blood pressure
control group as compared to the treatment group.
Finally, offering some contextualizing research, Patzer et al. (2015) studied the
state of ESRD treatment in the state of Georgia. They conducted a historical analysis of
ESRD treatment in the specific context of Georgia, an analysis which included 279
patients of ages 18-69 from 308 facilities over the period 2005-2011. In Georgia, the
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government requires dialysis centers to inform their patients of all treatment options,
including that of transplants, and that beginning the consideration process generally
requires a referral from a dialysis center. Accordingly, referral for transplantation from a
dialysis center has practical importance for treatment (Patzer et al., 2015). In Georgia, the
factors associated with centers being unlikely to refer patients for transplantation were
high-poverty. A higher patient to social worker ratio, and non-profit status for the dialysis
center and older age or white race for patients. However, these factors were not
necessarily indicative of patients’ odds of being waitlisted for a transplant. Overall, the
results of this study indicated that dialysis center referrals play an important part in
moving patients to waitlists, but that this may not be the decisive factor.
In general, the treatments for ESRD are hemodialysis and kidney transplants.
Hemodialysis is a necessary treatment and represents an external facility being used to
filter a patient’s blood of waste in place of natural kidney function. This treatment does
not do anything to alleviate the condition itself, only to keep it from being fatal. The only
cure for ESRD is transplantation, also known as renal replacement therapy.
Transplantation is an effective cure in the sense that both the donor and recipient in a
kidney transplant can survive with only a single kidney. This means that kidney donation
is one organ transplant that doctors can do from living donors and deceased donors. Some
recent advancements, such as a wearable artificial kidney, offer the intermediate
possibility of a better quality-of-life than full hemodialysis without a transplant, but these
technologies are still forthcoming. Preexisting nephrological care can predict better
overall outcomes and survival in ESRD patients, and dialysis centers play an important
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role in referring patients for transplantation. As alluded to in previous sections, however,
there remains a significant gap between kidney transplant waitlists and available donors.
Significance of Treatment to the Study
Overall, increased quality of ESRD care is the outcome of the study. This variable
takes the form of 30-day rehospitalization, as discussed in the following section because
reducing avoidable rehospitalization is one of the best measures of improves ESRD care
(Matthew et al., 2015). However, this is merely one practical outcome that is broadly
indicative of treatment quality and not the only one. Accordingly, the discussion of
overall ESRD treatment is not only in its importance as background information and how
it contextualizes hospitalization but also in shaping and characterizing the broader field of
treatment. For example, one reason why ESRD care may falter or fail relates to the selfcare component. Studies such as that of Ku et al. (2015) illustrate this by demonstrating
the long-term effects of self-care aspects such as blood pressure control on long-term
ESRD outcomes. The value of prior nephrology care (Gillespie et al., 2015) also supports
the importance of communicating with and educating patients as a key part of ESRD
treatment,
End-Stage Renal Disease and Hospitalization
As with many chronic and deadly conditions, hospitalization is a potential
consequence of ESRD. Hospitalization involves a patient being admitted to a hospital and
kept overnight for treatment (Matthew et al., 2015). Hospitalization is vastly expensive.
Lengthier hospital stays may also lead to complications such as bedsores, blood clots, or
muscular atrophy. Therefore, avoiding hospitalization where possible is desirable.
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Although most dialysis treatment is undertaken, at present, in outpatient clinics that may
or may not be associated with a hospital, outpatient treatment of this type is not
considered hospitalization; only inpatient treatment is germane to this section.
Inpatient hospitalization is the primary dependent variable in the current study for
several reasons. Firstly, as per Matthew et al. (2015) and the theoretical framework,
avoidable hospitalization and especially avoidable readmission are common in ESRD
patients relative to the general population. Rehospitalization creates significant personal
(Matthew et al., 2015) and societal (Liao et al., 2016) costs associated with ESRD.
Therefore, short of reducing ESRD incidence, reducing ESRD-related hospitalization is
likely the most effective way of diminishing the costs associated with the condition.
Secondly, many hospitalizations associated with ESRD are avoidable with better
treatment or better patient treatment adherence (Matthew et al., 2015). Better treatment
adherence makes reducing avoidable hospitalizations—and especially unnecessary
rehospitalizations—a priority as it suggests that reducing hospitalizations could be
associated with an improvement in care and patient outcomes instead of merely treated as
a cost-saving or practical measure. Third, as the following studies—and the following
section—demonstrate, hospitalization for ESRD disproportionately affects certain
groups. The outsized impact of ESRD on minority groups is both a reason to help remove
the problem and a potentially helpful tool for so doing. In identifying these groups that
are especially at risk, as the current study aims to do, it should be possible to develop
interventions that target at-risk groups and improve their ESRD hospitalization outcomes.
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Indeed, ESRD patients have the highest hospitalization rate for patients with any
chronic illness, even including heart disease and cancers (Lovasik et al., 2016). This
translates into extensive emergency room usage, and emergency room visits are an
especially costly form of hospitalization. Examining these issues, Lovasik et al. (2016)
conducted a historical study of all Medicare patients in the USRDS from 2005 and 2011
concerning emergency room utilization. Somewhat confounding the data, researchers
have found that some patients use the emergency room as a primary dialysis provider,
with over 50 visits in the first year. These patients were removed from the dataset. The
total resulting sample size was 769,228 patients, of which over 550,000 had at least one
emergency room visit in the study period. Furthermore, 55% of the sample had at least
one the first year following their ESRD diagnosis, and on average, patients had between
two and three emergency room visits annually in their first 3 years of ESRD. As per the
study,
factors associated with higher rates of ED [emergency department] use included
younger age, female sex, black (vs white) race, comorbid medical conditions,
Medicaid insurance (vs Medicare alone), catheter or graft hemodialysis access (vs
fistula), tobacco use, institutionalization, and more recent ESRD diagnosis.
(Lovasik et al., 2016, p. 1563)
The results quoted above provide further support for the idea that certain patients
are more likely to need hospitalization, and this extensive usage of expensive emergency
care suggests that hospitals could make considerable improvements in that dimension of
ESRD. On the other side of the issue, the results of a study by Goodrich, Schaubel,
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Smith, Merion, and Sharma (2016) demonstrated why a better understanding of ESRD
hospitalization and avoiding rehospitalization might be especially important to patients
with certain comorbidities, in addition to specific demographics. The Goodrich et al.
(2016) study explored ESRD-related hospitalizations for patients with a liver transplant
in addition to their ESRD. The study was historical in nature, including a matched sample
of liver transplant patients with and without ESRD, for a total of 7,019 patients. The
average hospitalizations per year were seven for liver transplant patients without ESRD
and 23 for those with ESRD. Goodrich et al.’s analysis showed that, after adjustment for
various covariates, the risk of hospitalization was 97% higher for liver transplant patients
with ESRD than without it. While these hospitalizations are unlikely to be preventable,
improved interventions could likely do much to equalize these figures.
Finally, another interesting effect of ESRD on hospitalization pertains to the use
of hospice care. Hospice care represents a form of end-of-life care in which patients who
have accepted the onset of death are cared for. Many patients suffering from chronic
conditions utilize hospice care. Despite their increased use of standard hospitalization,
ESRD patients are less likely to use hospice services than are patients with other chronic
conditions (Goodrich et al., 2016). The results of a historical study examining the usage
and costs of hospice for ESRD patients found that those patients who stayed in the
hospice less than 3 days, around 40% of the historical cohort, were less likely to die in
the hospital or in intensive care, but they had similar end of life costs. However, these
short stays were also associated with a higher chance of hospitalization. Overall, longer
hospice stays were associated with progressively less overall hospice costs and intensive
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procedures. Overall, end-of-life costs were quite similar, however, suggesting that there
may be no clear advantage in this context.
Overall, ESRD is the chronic condition most likely to lead to a patient’s
hospitalization, even compared to heart disease or cancer. Hospitalization, in the case of
ESRD represents a large part of its personal and societal costs. Therefore, reducing
hospitalization—and especially unnecessary rehospitalization—is likely the best way to
decrease the costs associated with ESRD while at the same time offering the chance to
improve care. ESRD hospitalization is also significantly more pronounced for certain
demographic groups and patients with certain comorbidities. ESRD patients also make
considerable use of emergency services, with most ESRD patients visiting the emergency
room in their first year of the condition and having multiple visits annually in the first 3
years. All of this indicates that hospitalization—and especially unnecessary
readmission—is the appropriate dependent variable for the current study and one of the
most important outcomes to target and reduce after ESRD incidence.
30-Day Readmissions
The specific variable of 30-day readmission is considered a measure of the
success or failure of treatment’s effectiveness during the first hospitalization (Matthew et
al., 2015). Thus, 30-day readmission represents a measure of the issues associated with
hospitalization. Sometimes, ESRD hospitalization is unavoidable (Matthew et al., 2015).
In general, however, another such unavoidable episode is unlikely to happen within 30
days of the first (Matthew et al., 2015). Accordingly, by measuring 30-day readmission,
the study is effectively measuring the quality of the ESRD care provided in the first
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hospitalization. While overall hospitalization might be another possible way of thinking
about this variable, the unavoidable hospitalizations associated with ESRD would skew
this in areas with a higher incidence of ESRD. As the following section will demonstrate,
gender may have correlates in both the severity of renal disease progression and the types
of care provided. These are not the issues under study, but rather how ESRD care can be
improved, especially through avoiding unnecessary readmission. Because most avoidable
ESRD-related hospitalizations take on the form of readmission as per the theoretical
framework (Matthew et al., 2015), 30-day readmission is the best way to measure
hospitalization as it pertains to and is indicative of qualify of ESRD care.
End-Stage Renal Disease and Demographics
As alluded to in multiple prior sections, demographics play a key role in multiple
aspects of ESRD. Demographics shape the rates of ESRD incidence, the rates of ESRD
hospitalization (Lovasik et al., 2016), the likelihood of being referred for renal
replacement therapy (Patzer et al., 2015), and many other aspects of ESRD. For this
reason, most of the key predictors and independent variables in this current study are
demographic in nature. The existing research indicates the importance of these variables
as predictors of ESRD incidence and outcomes.
Age
As with many—if not most—chronic conditions, ESRD incidence is affected by
age. However, traditional approaches to mapping the relationship between ESRD and age
have critical shortcomings. Specifically, as per Krishnaswami et al. (2016), most such
analyses dichotomized age into younger and older groups, where researchers categorized
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ESRD patients at age 65 years and older, 80 years and older, or both and treated this
overall in a linear fashion. Grouping by age is a somewhat natural approach if one wishes
to encapsulate age into a variable but may not be an accurate reflection of the true effect
of age on ESRD outcomes. The results of these studies often fail to make sense for
revascularization, although they do predict ESRD mortality acceptably well.
Krishnaswami et al. (2016) found that different arbitrary age cutoffs produce different
results and that a linear model of age could not predict repeat revascularizations.
However, a cubic spline model of age’s effects resulted in an improved model for age and
a consistent revascularization model. The results of this model’s use suggest how simple
and straightforward demographics categorization can result in more interesting data than
expected. Because of this result demonstrating age weakness as a linear predictor, age
was not chosen as a predictor in the current study.
End-Stage Renal Disease and Ethnicity
Race/ethnicity is another factor that strongly affects ESRD and related factors
(Lovasik et al., 2016). Interestingly, race does not only predict outright outcomes but also
the effects of other predictors. For example, dietary acid load is an important factor in
predicting the development of kidney disease and its progression over time (Crews et al.,
2018). While this is true in general, a large study by Crews et al. (2018) found that this
relationship holds to a significantly higher degree amongst Blacks than it does amongst
Whites. This result is interesting in that it suggests even the progression through the
various stages of renal disease may be significantly different across racial lines. However,
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a considerably larger body of research demonstrates more direct links between race and
ESRD.
However, more directly relevant to the current study is that race and ethnicity—
alongside other demographic factors—can have effects through the availability and
quality of care. Race and poverty were central to a study by Nee et al. (2017) on the role
of pre-ESRD nephrology care. Patients who have access to nephrology before
researching the ESRD are significantly associated with lower mortality and morbidity
from ESRD, as per prior research (Gillespie et al., 2015). Based on a retrospective cohort
study using a USRDS sample of 739, 537 patients from 2007-2012, Nee et al. (2017)
found two independent results: those in poverty, as measured by Medicare and Medicaid
eligibility, were significantly less likely to have undergone pore-ESRD nephrological
care and that both Blacks and Hispanics, relative to Whites, were significantly less likely
to have undergone pre-ESRD nephrological care. As per Gillespie et al. (2015), this puts
the impoverished and these racial minorities at greater risk for first year mortality. Thus,
overall, the race/ethnicity variable in the current study are supported by these results.
Another highly relevant result stemmed from Shah et al. (2018) 's research, who
studied gender, ethnicity, and access to hemodialysis care. As noted previously, access to
dialysis on a regular basis can decrease the risk of mortality up to 14 times relative to
emergency-only access (Cervantes et al., 2018). However, different types of hemodialysis
access have different outcomes as well; specifically, “Arteriovenous (AV) access confers
survival benefits over central venous catheters (CVC) in hemodialysis patients” (Shah et
al., 2018, p. 4). Based on another retrospective cohort study comprising 885,699

31
participants from 2004 to 2014, Shah et al. (2018) found that women have significantly
lower odds of having access to advantageous arteriovenous dialysis. Racial results were
more mixed: Blacks and Asians were more likely to use arteriovenous access than were
Whites, but Hispanics were less likely to. Given that the type of dialysis access patients
has conferred clear benefits in terms of their treatment, the results of Shah et al.’s (2018)
study offers significant support for the use of race and gender as predictors of ESRD
treatment outcomes.
More directly touching upon hospitalization was a study by Newman et al. (2016).
Specially, their research examined racial differences in hospitalization hos patients on
kidney transplant waitlist (for the deceased donor waitlist, in particular). The study
represented another example of a retrospective cohort study using USRDS data, with a
sample of 24,581 patients between 2005 and 2009. The researchers adopted a novel
cluster analysis approach and found that, based on the results, patients who were
hospitalized were less likely to receive transplants, and Blacks and Hispanics were more
likely to be hospitalized than were Whites. However, they noted that adjusting for the
role of hospitalization in determining the likelihood of being given a kidney transplant
did not significantly reduce the level of disparity on the waitlist itself. These results
encapsulate two important ideas relevant to this study. Firstly, the fact that hospitalization
decreases an ESRD patient’s chances of being given a kidney transplant represents
another reason supporting the importance of hospitalization as an outcome to be reduced.
Secondly, the results provide strong support for the use of race as a primary demographic
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predictor of hospitalization, as their results found that minorities were significantly more
likely to undergo ESRD-related hospitalization.
Considering all of this, one final study of interest is less statistical and more
patient-centric. Black ESRD patients tend to have a significantly higher chance of nonadherence to treatment guidelines (Savage, 2017). The outsized impact on Black ESRD
patients is troubling in that it suggests an already disadvantaged demographic may act to
make their own situation worse. Noting this, Savage (2017) sought to study the reasons
why and used a mixed-methods approach that combined qualitative interviews and
quantitative survey research. The study included 46 Black ESRD patients, 27 of whom
participated in in-depth semi-structured interviews. Thus, although the sample size was
not large enough to create significant quantitative effects, the qualitative results remain
strong. The mixed-methods analysis overall suggested that the reason for this problematic
non-adherence can be characterized as a response to perceived racism. Rather than
explicit, high-level racism, the study participants characterized their experiences with the
medical community as being affected by “everyday racism,” a low-level but pervasive
type of racism. This experience of racism served to diminish the participants’ perceptions
of the medical establishment, resulting in decreased attention to guidelines and resulting
in non-adherence to those guidelines. This result suggests that racial differences in
treatment may stem from more than simple racial predispositions. This principle may
potentially extend to other demographic factors as well.
Overall, there is no lack of evidence for the importance of demographics in
shaping ESRD and, more relevantly, ESRD treatment, and treatment outcomes. The most
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prominent demographic in the results was race/ethnicity, a demographic that occurred in
almost every study. Thus, there is clear and strong support for race as an independent
variable in the current study. Gender and poverty/employment were also supported as
lesser predictors of ESRD outcomes and this germane to the study as independent
variables. Age was also supported as a predictor of ESRD-related outcomes. However,
the support for age occurred in such a way as to make it evident that age was not a
variable well served by use as a linear predictor, as it would be in the present study.
Therefore, age was not included in the current study. Finally, one study (Savage, 2017)
gave insight into how even low-key perceived discrimination based on a demographic
factor, such as race, can significantly affect treatment outcomes for that demographic by
creating treatment guideline nonadherence. Such nonadherence is problematic and may
result in significantly worse treatment outcomes, contributing to unnecessary hospital
readmission.
End-Stage Renal Disease and Gender
Gender is a significant predictor of ESRD-related outcomes. This has already
been referenced in several of the studies discussed above, but this section will provide a
further specification of the prior results regarding gender. One such result is that of a
study by Shah et al. (2018), which focused on the differing access of different
populations to different treatment types. Their results indicated that women have
significantly lower odds of having access to the advantageous arteriovenous dialysis. The
lack of access to dialysis means that the treatment outcomes for women with ESRD may
differ from those of men, which may affect the rate of ESRD-related (re)hospitalization.
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Another study by Shah, Thakar, and Leonard (2018) found similar structural results of
gender on ESRD outcomes. Specifically, using a sample of nearly 50,000 ESRD patients
from the USRD, they found that women are, overall, 6% less likely than are men to be
given enough information about kidney transplantation, thereby significantly effecting
the quality-of-care provision.
On the other hand, an analysis by Neugarten and Reckelhoff (2015) of prior
research suggested that there are sex differences in the incidence and progression of
kidney disease across multiple animals. In general, the researchers found that ESRD was
more common in male animals but that they could easily replicate this outcome using
hormonal treatments. The results suggested that sex hormones, rather than differences in
the physical structure of the two genders, is likely responsible for gendered differences in
ESRD (Neugarten & Reckelhoff, 2015)
There is evidence for gender as an important variable; therefore, from both a
social standpoint and a medical one, gender significantly impacts ESRD outcomes.
Interestingly, these social effects on treatment disadvantage women, who receive worse
types of care and worse information about care. Conversely, research suggests that—
based on multiple animal models—men are more medically at risk from ESRD and more
likely to develop it due to sex hormones. These two effects work at cross-purposes to one
another, making it not immediately apparent which gender should be expected to be a
more meaningful predictor in the study.
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Employment Status
No studies explicitly address employment status. Instead, employment status is
something of a proxy for another that is highly relevant: poverty. It is impossible to
establish poverty based on the USRDS data that will be utilized in the current study.
However, unemployed people are at a significantly higher risk for poverty, making
employment status the closest reasonable proxy for poverty available in the data. Results
for the importance of poverty are as follows. Patzer et al. (2015) found that impoverished
patients are significantly less likely to be referred for a kidney transplant in Georgia.
Given that transplants are the only true cure for ESRD, and transplants require a referral
from a dialysis center, this indicates that the impoverished may have significantly lower
access to a cure for ESRD. The lowered access to cures in turn, may put the impoverished
at greater risk of hospitalization and poor treatment outcomes from ESRD.
Nee et al. (2017) found that the impoverished are significantly less likely to have
to experience pre-ESRD nephrology care during the progression of their kidney disease.
Considering that pre-ESRD nephrology is significantly associated with improved patient
outcomes and a lack thereof is related to significantly higher rates of first-year ESRD
mortality, this suggests that the impoverished are likely to have poor treatment outcomes.
Poor treatment outcomes may also suggest that the impoverished are significantly less
likely to be knowledgeable about ESRD care and that they, therefore, may have worse
self-care outcomes in following treatment guidelines following hospitalization.
While employment status is likely not the best proxy for poverty, it is the best
available in the USRDS dataset. Poverty has been significantly linked with at least two
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different outcomes that predict worse treatment: a lack of transplant referrals and a lack
of pre-ESRD nephrology care. Therefore, there is reason to believe that poverty—
measured through employment status—may significantly affect ESRD hospitalization
and quality of care.
Spoken Language
Studies such as those of Gillespie et al. (2015) and Nee et al. (2017) illustrate the
vast importance of patient-caregiver interaction and patient education. Both studies
indicate that something as simple as a prior history of nephrology care can significantly
impact patients’ likelihood of dying from ESRD. Indeed, the extra mortality from those
without a history of nephrology care comes especially in the first year, suggesting further
the role of the educational aspect of such care in preventing poor treatment outcomes.
Furthermore, Savage (2017) demonstrated the importance of patients’ willingness to
cooperate in their own care, noting how even the perception of everyday racism can make
patients likely to disregard their treatment guidelines.
While none of these directly indicate language as a barrier, they do indirectly
suggest it. Patients whose preferred spoken language is not English may struggle to
receive treatment instructions or fail to fully understand those treatment instructions even
when they think they do understand them. Furthermore, most of those who would prefer a
spoken language such as Spanish are at risk for the kind of everyday racism addressed by
Savage (2017) over language and race/ethnicity. While indicating a language other than
English as a preferred spoken language does not guarantee a language barrier, it is
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strongly suggestive of one, and existing research suggests several reasons why such a
barrier may be significantly related to ESRD treatment outcomes.
Methodological Precedents
The primary discussion of the study’s methodology and the justifications for it
will be in section two of this document, which focuses exclusively on methodological
issues. However, one methodological aspect that is more in the domain of the literature
review is to examine the types of research methodology used by prior studies. This
examination of methodological precedent provides a look at how similar studies have
been undertaken in the past, thereby strengthening the case for adopting an approach that
is “tried and true” as it were. In this study, the proposed research method is that of a
nonexperimental historical, correlational design, also called a retrospective cohort study.
The current study will draw its data from the USRDS, a large database of renal data.
As previously alluded to, this methodological approach has a highly significant
precedent. Of the studies included in this review, a majority adopted this same approach.
Butler et al. (2015) used the USRDS dataset to analyze cancer risks in ESRD patients.
Like the current study—and most of those following— Butler et al. (2015) limited their
data to the data of Medicare patients in the USRDS because this subset of the data
contains considerably more complete data than does the overall USRDS dataset. Collins
et al. (2015) also used the USRDS—indeed, their study focused on an analysis of the
dataset’s history and advantages. Gillespie et al. (2015) also utilized the USRDS, with a
cohort of 443,761 patients, to study the relationship between a history of nephrological
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treatment and ESRD mortality. At the time of publication, their study represented the
largest cohort study of ESRD.
Gómez‐Puerta et al. (2015) used a USRDS dataset to analyze the comorbidity of
ESRD and lupus erythematosus. Even this much more specialized study was able to find
a cohort of over 12,000 participants in the USRDS. Similarly, Kaminski et al.’s (2015)
study of ESRD and foot-related complications used a USRDS cohort of over 45,000. Ku
et al. (2015) adapted USRDS data for a more specialized purpose. Specifically, they used
the data to follow up on the patients who had been involved in a clinical trial of blood
pressure control and determine that, even though the trial had yielded no immediate
results at the time, the two arms had different long-term outcomes. Liao et al. (2016)
found the USRDS an ideal setting for a study that was designed to apply a novel big data
analysis approach in healthcare.
Lovasik et al. (2016) also used a USRDS cohort to study emergency room
utilization by ESRD patients. In another study about the implications of prior nephrology
care, Nee et al. (2017) mustered a cohort of over 700,000 patients from the USRDS data.
Newman et al. (2016) drew upon a much smaller cohort of 24,000 to assess
hospitalization and race. Perhaps the largest USRDS cohort used was 1.3 million patients
in Nguyen et al.’s (2017) study of renal cancer. This list is not exhaustive, but already
considerable. A few of the other reviewed studies that did not draw upon the USRDS
dataset still adopted retrospective cohort designs using different and smaller data sources.
Given its size, availability, and the completeness of its data for a large portion of the
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population (Medicare patients), the USRDS and the cohorts it makes available for study
are ideal for most quantitative analyses about ESRD.
Research Gap
The primary impetus for this study lies in its practical significance. As per the
theoretical framework (Matthew et al., 2015), unnecessary and avoidable readmissions
represent a significant source of expense for ESRD patients and society. ESRD is a
chronic condition with the highest risk of hospitalization (Lovasik et al., 2016). There are
significant racial disparities in both the incidence and treatment outcomes of ESRD.
These practical issues, however, are not the only motivation for the study.’ Instead, they
are parallel to an academic research gap, which also serves as a secondary motivation for
the study.
Three calls for further research highlight this research gap. First and foremost, of
these is the call by Matthew et al. (2015). In keeping with the theoretical framework of
the current study, this calls for further research highlighted the need for more research
into the factors predictive of unnecessary ESRD-related hospital readmission to better
target interventions to reduce the incidence thereof. Secondly, tying into this was a call
for research by Newman et al. (2016) for such future research on further social context
factors and their impact on ESRD treatment outcomes such as hospitalization. From this
call for research, the current study will adopt the contextual factor of employment status
and the other demographic variables chosen in concert with the literature review. The
final call for research was for research into factors that may contribute to or create race
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and gender disparities in treatment and outcomes (Shah et al., 2018). To answer this call
for research, the current study will focus on the role of these demographic predictors.
Summary
In conclusion, this literature review examined the study’s theoretical foundations
and five key themes. These themes were the significance of ESRD as a problem, the
complications, and comorbidities of ESRD, ESRD treatments, ESRD and hospitalization,
and ESRD and demographics. This review highlighted many aspects of ESRD. The
condition is the fifth and final stage of chronic kidney disease, and ESRD rates are
stabilized but still slightly increasing in the developed world, while incidence is rampant
in the developing world. ESRD is often caused by diabetes and hypertension and may
lead to renal cancer complications, which has a nearly 10% incidence in the 5 years
following ESRD. A kidney transplant is the only cure for ESRD. Failing that, ESRD is
treated by hemodialysis, in which an external device takes over the kidney’s function of
filtering waste out of the bloodstream.
Of chronic conditions, ESRD is the most likely to cause hospitalizations. ESRD
patients are highly likely to use the emergency room, averaging between two and three
visits annually. ESRD hospitalization is expensive and often avoidable, suggesting this to
be one of the best ways of improving ESRD care going forward, in multiple ways.
Demographics can help predict many aspects of ESRD care and outcomes. Important
demographics include age, race/ethnicity, gender, and poverty. Further research is needed
about the factors predicting ESRD hospitalization, especially unnecessary readmission.
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The importance of the key variables which are found in this study is highlighted.
The independent variables are gender and race/ethnicity, whereas the dependent variables
are 30-day readmission rates and ESRD-related hospitalization risk, respectively. This
concludes the literature review.
Definitions
End-stage renal disease (ESRD): ESRD is the fifth and final stage of kidney or
renal disease, at which point the kidneys have ceased to function (Robinson et al., 2016).
Gender: Gender is the participant’s gender as male or female. Gender will
function as an independent variable.
Hemodialysis (dialysis): Dialysis is the process of filtering the bloodstream
through an external device to filter out waste that the kidneys would normally filter
(Robinson et al., 2016).
Race/ethnicity: Race/ethnicity is the biological race or census-indicated ethnicity
of a person and will take the possible values of Caucasian, Black, Hispanic, Asian, Native
American/Alaska Native, and Other. Race/ethnicity will function as an independent
variable.
United States Renal Data System (USRDS): The USRDS is a comprehensive
source of information about renal disease that includes a wide array of related topics such
as disease severity, hospitalizations, pediatric populations, prescription drug use, and
chronic kidney disease and the transition to ESRD (Collins et al., 2015).
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30-day readmission: 30-day readmission indicates the number of times a patient
is re-hospitalized within 30-day of initial ESRD-related hospitalization. 30-day
readmission will function as a dependent variable.
Assumptions
Assumptions represent foundational aspects of the study that cannot be tested and
must be assumed to be true (Merriam & Tisdell, 2015). There are several assumptions
underlying the current study. The first is that a quantitative, retrospective cohort study
can provide meaningful data on ESRD. This assumption is inherent in quantitative
resources but well supported by the popularity of this approach in medical research. The
second is that the USRDS provides complete and accurate data regarding patients. The
number of prior studies that have also used the USRDS dataset supports the validity of
this assumption. I also assumed that the Medicare and Medicaid data in the USRDS are at
least a decent proxy for the overall dataset. The study also assumes that demographics
and other predictors can significantly influence the hospitalization rates of ESRD
patients. Though other research supports this association, these studies—like the current
study—cannot prove causation. I also assumed that identifying the populations at greatest
risk for unnecessary readmission to a hospital setting will have tangible benefits for
policy and research.
Scope and Delimitations
Delimitations represent the soft limitations of a study, those imposed by the
researcher (Merriam & Tisdell, 2015). Firstly, the current study is delimited to ESRD
because, as described in the significance section of the literature review, ESRD is a
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condition of great prevalence and which creates high costs. The current study is delimited
to studying hospitalization and 30-day readmission. This study will only look at
hospitalization and 30-day readmission because, as per Matthew et al. (2015) and other
results in the literature review, reducing the costs associated with ESRD while improving
care can likely be most effectively done by reducing the number of unnecessary ESRDrelated hospitalizations. The study is delimited to the United States because USRDS data
are limited to the US context. As with many other USRDS studies, the current study was
delimited to the Medicare and Medicaid data in the USRDS because—due to the
government-funded nature of these health insurance programs—their patient data are
much more fully available compared to data for patients with private insurance. The
current study did not necessarily generalize well outside of the Medicare and Medicaid
cohort, but this is a tradeoff that many prior researchers have also deemed acceptable
because of the significant corresponding benefits of the USRDS as a source of data.
Significance, Summary, and Conclusions
Significance
The current study is significant both in practice and theory. Practically, it is
important because ESRD is a global health crisis. While ESRD rates have stabilized in
the United States, they are still increasing with time (Wetmore & Collins, 2016). ESRD
disproportionately affects vulnerable populations (Mendu et al., 2016), especially those
of Blacks and Hispanics, and bears a high burden from both an economic (Wang et al.,
2016) and quality-of-life (Raspovic et al., 2017) standpoint. Economically speaking,
ESRD patients are the most likely to be hospitalized out of patients with any chronic
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disease, even cancer and heart failure (Lovasik et al., 2016). They are also at significant
risk of rehospitalization (Matthew et al., 2015). Unplanned rehospitalizations are
expensive for both the patient and the hospital; therefore, reducing 30-day readmission of
ESRD patients as a measure of rehospitalization represents an important goal from a
practical perspective. The results of this study will help hospitals and health
administrators understand which patients are most at risk of unplanned rehospitalization.
Doing so may contribute to both social and practical change by providing data necessary
to develop targeted interventions to reduce 30-day readmission rates in vulnerable
populations. Reducing 30-day readmission rates for ESRD will improve outcomes for
both those populations and the hospitals themselves. Theoretically speaking, the study
addresses a gap in the academic literature characterized by a need for more research to
determine ways of reducing readmission (Matthew et al., 2015), ESRD hospitalization
research that considers appropriate contextual and socioeconomic predictors (Newman et
al., 2016), and more research on race and gender gaps in ESRD hospitalizations (Shah et
al., 2018).
Summary and Conclusions
In summary, ESRD is a serious problem in today’s world. Though there is a lower
occurrence of ESRD the developed world, it is far from defeated. Thus, while ESRD
diagnoses are increasing in general, the problem is that minorities—and especially
minority women—may be at especially high risk for poor outcomes. This problem is
significant because ESRD is a heavy economic burden not only on patients but on
caregivers and society (Wang et al., 2016). To address this problem, the purpose of this
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quantitative nonexperimental historical, correlational design is to determine the extent to
which gender and race/ethnicity predict 30-day readmission rates after hospitalization for
ESRD patients. In keeping with this purpose, the study will be guided by three research
questions: (a) To what extent, if at all, does patient gender predict 30-day hospital
readmission rate for ESRD patients in the United States? (b) To what extent, if at all,
does patient race/ethnicity predict 30-day hospital readmission rate for ESRD patients in
the United States? and (c) Are there any significant interaction impact between gender
and race/ethnicity in predicting 30-day hospital readmission rate for ESRD patients in the
United States?
A significant review of the academic and professional literature reveals the
importance of 30-day readmission as an outcome and demographics as predictors of
ESRD-related outcomes. Drawing data from the USRDS and Data.gov historical datasets,
the current study will examine which of these predictors most significantly drive
unnecessary ESRD-related hospital readmission. These results have important
implications in informing interventions to reduce ESRD hospitalization, thereby reducing
both the personal and societal costs associated with the disease. This section has provided
an overview of the current study and a review of the literature. Now, in section two of the
study, the methodological considerations for undertaking it are laid out.
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Section 2: Research Design and Data Collection
Introduction
The purpose of this quantitative study was to determine the extent to which
gender and race/ethnicity predict 30-day readmission rates after hospitalization for ESRD
patients. This section of the study outlines the methodology by which it was undertaken.
In the first section I examine the quantitative methodology and the nonexperimental,
historical, correlational/retrospective cohort design that I adopted for the study. Secondly,
I examine various aspects of the research method. These include the population, data
sources, the operationalization of variables, and the data analysis. Next, I review threats
to validity and ethical issues. The section concludes with a summary.
Research Design and Rationale
The nature of the current study was a quantitative, historical, correlational design.
Quantitative research is an approach that examines the world from a numerical, objective
perspective (Bryman, 2016). Quantitative research is aimed at examining issues that can
be quantified, such as those for which there are existing, validated quantitative
instruments to measure, or for understanding the nature of the relationships between two
or more variables (Bryman, 2016). Overall, the greatest strength of a quantitative study is
that its results are based solely on objective data measured using carefully validated
instrumentation. The numerical or otherwise closed-ended nature of this type of data also
means that quantitative research can practically process and analyze large sample sizes
(Bryman, 2016). Quantitative research creates results that can be generalized and whose
strength can be measured using statistical techniques such as power analyses and
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confidence intervals using these larger sample sizes. All of this made the quantitative
approach a strong fit for the current study because it is used to examine the relationships
between easily quantified and measured variables. All the predictor and outcome
variables in the research questions—gender, race/ethnicity, 30-day hospital readmission
rate, and medicate claims—were either quantitative by nature or easily assessed
sociodemographic variables. Furthermore, all three of the research questions guiding the
current study pertained to the nature of the relationship(s) between these variables, and,
as the next section demonstrates, large datasets were available containing these data.
The specific research design was that of a historical, correlational design.
Correlational research is a type of quantitative research that focuses on uncovering the
correlational or associational relationships between variables (Johnson, 2001).
Correlational research cannot establish stronger causal links as an experiment can, but
correlational research has significantly less stringent data collection limitations in
exchange for this drawback. Rather than creating a controlled experiment in which
variables are manipulated, the correlational researcher can collect data from a crosssectional or historical sample (Johnson, 2001). Historical data are preferable as such data
tend to be readily available without resource-intensive data collection on the part of the
researcher and offer large sample sizes when historical repositories of the relevant data
can be found. Because such historical data exist for the variables under study in the
current study, a historical approach was deemed appropriate.
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Methodology
Population
The study population for this study was all United States patients who suffer from
ESRD and have been hospitalized because of their ESRD. For practicality and data
availability, the study population was further limited to patients whose ESRD
hospitalizations resulted in Medicare claims and those hospitalized during the period
2017-2018. Although I placed a special interest on the data for Blacks and Hispanics, this
study had no racial delimitations. Furthermore, for this research I did not use other
demographic factors to delimit the population of the study, allowing the use of the full
range of publicly available data.
Power Analysis and Sample Size Estimation
I used G*Power v3.1 software to perform a power analysis and determine the
necessary minimum sample size for the study (Faul et al., 2009). A statistical power of
80% is relatively standard and was used (Charan & Biswas, 2013). Similarly, I used a
medium effect size, as represented by d = 0.5 or f2 = 0.15 (Ferguson, 2009). A
significance of 0.05 is also a standard value, although it must be noted that this only
assures statistical significance, not clinical significance. For the ANOVA/t tests, a
minimum sample of 126 was required. For the regression analysis, a minimum sample
size of 77 should be achieved. Because the data were drawn from a very large historical
database, meeting and exceeding these minimum sample sizes presented no difficulty.
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Sources of Data
The study's data were drawn from two secondary sources: Data.gov and the
USRDS. Data for RQ1 to RQ3 were drawn from the dataset available through the
USRDS. The USRDS is a national registry for data on people with ESRD in the United
States, funded by the National Institutes of Health, National Institute of Diabetes and
Digestive and Kidney Diseases. The USRDS is a comprehensive database of all renal
patients in the United States, although many of the more specialized data are only
available for patients with Medicare claims. Because data regarding hospitalizations are
limited to Medicare patients in this dataset, the study drew on the Medicare-only portion
of the USRDS dataset. The USRDS data is in part available freely for any use through an
annual report. However, more complete data for research and analysis are also available
upon request. Therefore, for the present study I requested the use of data for the 20162018 period for Medicare patients and the variables of hospitalization, 30-day
readmission, race/ethnicity, and gender. All these variables were available in the
Medicare dataset as per the USRDS website.
For both sources of data, I carried out all original sampling and data collection
through the submission of Medicare claims for hospitalization. As a result, there was no
significant risk of sampling bias or other undesirable sampling effects as, rather than
random or convenience, the sampling simply included all eligible data points.
Operationalization of Variables
The study variables were as follows:
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Gender: Gender was operationalized as a binary variable recording the
participant’s gender as male or female. Gender functioned as an independent variable.
This data was recorded as part of the ESRD records accessed during data collection.
Race/ethnicity: Race/ethnicity was operationalized as a categorical variable with
the possible values of Caucasian, Black, Hispanic, Asian, Native American/Alaska
Native, and Other. Race/ethnicity functioned as an independent variable. This data was
recorded as part of the ESRD records accessed during data collection.
30-day readmission: Thirty-day readmission was measured as an ordinal variable
indicating the number of times a patient is rehospitalized within 30 days of an initial
ESRD-related hospitalization. Thirty-day readmission functioned as a dependent variable.
This data was recorded as part of the ESRD records accessed during data collection and
was gleaned by comparing data points with matching other characteristics.
Data Analysis
Prior to any data analysis, I screened the historical data for clear outliers, and
these were removed so that they did not unduly skew the results. As I used historical data,
no cleaning of incomplete responses was necessary. All data analysis were carried out
with the aid of SPSS statistical software in the latest version. The research questions and
corresponding hypotheses tested for the study were as follows:
Research Questions and Hypothesis
RQ1: To what extent, if at all, does patient gender predict 30-day hospital
readmission rate for ESRD patients in the United States?
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H01: Patient gender does not predict 30-day hospital readmission rate for
ESRD patients in the United States.
H11: Patient gender predicts 30-day hospital readmission rate for ESRD
patients in the United States to a statistically significant degree.
RQ2: To what extent, if at all, does patient race/ethnicity predict 30-day hospital
readmission rate for ESRD patients in the United States?
H02: Patient race/ethnicity does not predict 30-day hospital readmission rate
for ESRD patients in the United States.
H12: Patient race/ethnicity predicts 30-day hospital readmission rate for ESRD
patients in the United States to a statistically significant degree.
RQ3: Is there a significant interaction between gender and race/ethnicity in
predicting 30-day hospital readmission rate for ESRD patients in the United
States?
H03: There is not a significant interaction between gender and race/ethnicity
in predicting 30-day hospital readmission rate for ESRD patients in the United
States?
H13: There is a significant interaction between gender and race/ethnicity in
predicting 30-day hospital readmission rate for ESRD patients in the United
States?
In keeping with the split datasets described in the previous section, I also split the
data analysis. First, the analysis began with simple descriptive statistics to describe both
datasets. Then, RQ1 through RQ3 were answered with regression analysis. I carried out
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three individual regression analyses to answer RQ1, RQ2, and RQ3. These analyses used
a type of regression appropriate to the predictors; this was simple linear regression in
most cases. To test the hypotheses, I tested the coefficients of regression and r2 values
for these regression models to see if they differed significantly from zero. Alternately,
RQ1 could be answered using a different-sample comparative t test. Multiple regression
involves using both all the relevant predictors as well as their interaction terms. When
these interaction terms have a coefficient of regression significantly different from zero,
there is a moderating effect between those two variables (Bolin, 2014). In addition, the
overall r2 and individual regression coefficients tested the significance of the overall
combined model and individual predictors within the combined model.
Before undertaking these tests, I tested the assumptions of the corresponding
regression models. These assumptions are the normality of the variables, which was
tested by a Shapiro–Wilk test, homoscedasticity, which I tested through a Breusch–Pagan
test, the linearity but not perfect collinearity of variables, and the independence of the
error terms. If one or more of these assumptions were violated, then I sought a more
appropriate alternate regression technique.
Threats to Validity
Validity and reliability are an intrinsic part of any research (Merriam & Tisdell,
2015). The reliability of a study relates to the accuracy and replicability of its results. In
this regard, the validity and reliability of the current study was strong. All variables used
in the study were drawn from historical data, but each holds an intrinsic value rather than
an attempt to quantify some construct. Furthermore, the data themselves are drawn from
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a historical, governmental database from which large amounts of data are available.
Using a governmental database for this study means that any researcher wishing to
replicate the study could do so by using the same set of USRDS data and analyzing them
in the same fashion. Therefore, the reliability of the current study should be strong.
Validity is divided into internal and external validity (Merriam & Tisdell, 2015).
Internal validity refers to how well the study fits together and answers the questions it set
out to answer. The current study achieved significant internal validity through careful
alignment of all the study components in a chain running from the problem to the purpose
of the research questions to the data collection variables. However, one threat to internal
validity is that the research design cannot establish causation, only
association/correlation. This threat was countered by carefully acknowledging the
correlational nature of the results when reporting them and taking care not to fall into the
erroneous use of causal language.
The large sample size afforded by the USRDS dataset, along with the Data.gov
dataset, offers a strong basis for external validity, as quantitative results gain external
validity and generalizability through a large sample size. However, one threat to this is
that the data included were only for Medicare and Medicaid patients. While there is no
reason to believe this section of the population has fundamentally different ESRD
outcomes, this still raises whether the results can be generalized to the entire population.
Nonetheless, so long as the researcher acknowledges this limitation in reporting the data
and results, its effect on validity was limited.
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Ethical Procedures
The current study is quantitative in nature and involved the use of publicly
available, de-identified archival data. Therefore, the current study was expected to pose
minimal ethical concerns for participants as the study does not involve collecting or
publishing of any data that are not already publicly available. My personal views and
biases did not color the results, as the study's raw statistical conclusions were presented
as a part of data analysis and reporting. Based on these statistical results, a reader may
determine for themself whether my conclusions were valid. Nonetheless, I took care to
avoid any bias, as I has some personal stake in the study’s outcome because of having
lost close family members to ESRD.
Summary
In summary, the purpose of this study is to determine the extent to which gender
and race/ethnicity predict 30-day readmission rates after hospitalization for ESRD
patients. This purpose was addressed through the use of a quantitative nonexperimental
historical correlational design, also known as a retrospective cohort study. Key study
variables included gender, race/ethnicity, and 30-day readmission. These data were
gathered from two different historical databases, the USRDS for the first set and
Data.gov for the second. These data were readily and publicly available, allowing me to
easily access them. Data analysis include descriptive statistics and multiple regression.
The data analysis results served to test the study hypotheses and provide valuable insight
into the predictors of ESRD-related hospitalization, which can be used to shape
interventions to improve ESRD hospitalization-related outcomes. This section has laid
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out the methodological considerations for the current study. Once I completed this study,
the following section, Section 3, provided explanation of the results and findings of the
analysis.
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Section 3: Presentation of the Results and Findings
ESRD continues to be a problem in the United States, with over 120,000 new
cases in 2014 alone and over 660,000 total cases in treatment (Saran et al., 2017). The
problem seems to be even worse for certain races/ethnicities, both in terms of incidence
rate, a higher risk of being affected by ESRD (Crews et al., 2018), and worse treatment
access (Patzer et al., 2015). In other words, the problem is that minorities, especially
minority women, may be at particularly high risk for poor outcomes related to ESRD
(Collin et al., 2015; Robinson et al., 2016). Given that ESRD takes a heavy economic toll
not only on patients but on caregivers and society (Wang et al., 2016), it is important to
identify whether ESRD does continue to disproportionally affect certain groups more
than others. In knowing this, interventions could target those most affected and therefore
have the greatest positive impact. Unplanned rehospitalizations are an expensive burden
that falls on both patients and the hospitals that treat them. Thus, reducing readmission
rates is important for both practical and altruistic reasons. With the present research I
aimed to shed light on race and gender's role on ESRD-related rehospitalizations, as this
is a research gap in the literature.
In this chapter, I review the research questions and hypotheses followed by a
discussion of the methodology, research design, and data collection approach. Next, I
present the descriptive statistics for the variables of interest and the results of several
regression analyses that were conducted to address the research questions to determine
the extent to which gender and race/ethnicity predict 30-day readmission rates after
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hospitalization for ESRD patients. Lastly, I discuss the summaries of the findings and
discuss the implications of the findings for the present hypotheses.
Research Questions and Hypotheses
The present research and data analyses were guided by the following research
questions and hypotheses:
RQ1: To what extent, if at all, does patient gender predict 30-day hospital
readmission rate for ESRD patients in the United States?
H01: Patient gender does not predict 30-day hospital readmission rate for
ESRD patients in the United States.
H11: Patient gender predicts 30-day hospital readmission rate for ESRD
patients in the United States to a statistically significant degree.
RQ2: To what extent, if at all, does patient race/ethnicity predict 30-day hospital
readmission rate for ESRD patients in the United States?
H02: Patient race/ethnicity does not predict 30-day hospital readmission rate
for ESRD patients in the United States.
H12: Patient race/ethnicity predicts 30-day hospital readmission rate for ESRD
patients in the United States to a statistically significant degree.
RQ3: RQ3: Is there a significant interaction between gender and race/ethnicity in
predicting 30-day hospital readmission rate for ESRD patients in the United
States?
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H03: There is not a significant interaction between gender and race/ethnicity
in predicting 30-day hospital readmission rate for ESRD patients in the United
States?
H13: There is a significant interaction between gender and race/ethnicity in
predicting 30-day hospital readmission rate for ESRD patients in the United
States?
Methodology and Research Design
Rationale for the Present Research Design and Methodology
I used a quantitative nonexperimental, correlational methodology using historical
data for the present research. This approach was necessary because random assignment
was not possible with the demographic variables of interest. In other words, people
cannot be randomly assigned to be male or female, for example.
Although causal claims cannot be confidently made with this approach, regression
analyses could inform both the strength and the direction of the relationships between
gender, race/ethnicity, and readmission rates for ESRD patients (Gallo, 2015;
Montgomery et al., 2012). Thus, the independent variables were gender and
race/ethnicity, whereas the dependent variables were 30-day readmission rates and
ESRD-related hospitalization risk.
Validity and Reliability
The inability to draw causal inferences due to the nonexperimental approach does
limit the internal validity of the research. In other words, because the variables of interest
are measured and not manipulated, the research is correlational, and the associations
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between variables are also inevitably measured and not manipulated (Thompson et al.,
2005). The use of real historical hospital data does increase the reliability and external
validity of the research, as it is easier to generalize the findings to other real patients. The
obtained hospital data spans from 2007 to 2017, limiting the reliability and external
validity of the research by limiting the ability to make inferences about ESRD-related
hospitalization rates prior to 2007 and after 2017.
Data Collection, Sample, and Sampling Approach
As stated, the study population was U.S. patients who suffer from ESRD and have
been hospitalized because of their ESRD with Medicare claims from the period 20172018. Although I placed a special interest on the data for Blacks and Hispanics, this study
had no racial delimitations. A minimum sample size of 77 of ESRD patients were
recruited for this study.
The data was gathered from two different historical databases: the USRDS for the
first set and Data.gov for the second. This data was readily and publicly available,
allowing me easy access. The large, national datasets available ensure that meeting the
minimum sample size requirements was easily achieved and exceeded. The research
sample’s gender and race/ethnicity were collected using a survey approach. For
readmission rates, data was collected by the hospitals and did not require self-reporting
on the part of the patients.
For the present study I requested the use of data for the 2016-2018 period for
Medicare patients and the variables of hospitalization, 30-day readmission, race/ethnicity,
and gender. All these variables were available in the Medicare dataset as per the USRDS
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website. The study drew on the Medicare-only portion of the USRDS dataset because
data regarding hospitalizations were limited to Medicare patients in this dataset.
Instrumentation
The data in the USRDS comprised actual health outcomes. Given that the data
comprised actual health outcomes rather than self-report measures provided by
participants, the data in the USRDS was itself extracted from claims-based and
enrollment data obtained from the Centers for Medicare & Medicaid Services. The
USRDS data is in part available freely for any use through an annual report. However,
more complete data for research and analysis are also available upon request.
Results and Analyses
Descriptive Statistics Analysis
Before conducting analyses to test the hypotheses, I conducted analyses to obtain
descriptive statistics for variables of interest: gender, race/ethnicity, and 30-day
readmission rates after hospitalization. This was done for each of these variables for the
data from years 2007 to 2017. The descriptive statistics in terms of mean and standard
deviation can be found in Table 1. In terms of gender differences, the sample of the study
consisted of two groups, which were male samples and female samples. In terms of
race/ethnicity differences, the sample of the study consisted of four groups, which were
Non-Hispanic White, Black, Hispanic, and Other/Unknown race.
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Table 1
Descriptive Statistics for Gender, Race/Ethnicity, and 30-Day Readmission Rates After
Hospitalization (Percentages).
Year

Statistic

2007 M
SD
2008 M
SD
2009 M
SD
2010 M
SD
2011 M
SD
2012 M
SD
2013 M
SD
2014 M
SD
2015 M
SD
2016 M
SD
2017 M
SD

Female

56.15
1.72
56.02
1.69
55.92
1.66
55.76
1.62
55.54
1.58
55.41
1.55
55.22
1.52
55.05
1.46
54.94
1.45
54.88
1.43
54.77
1.40

Male

43.85
1.72
43.98
1.69
44.08
1.66
44.24
1.62
44.46
1.58
44.59
1.55
44.78
1.52
44.95
1.46
45.06
1.45
45.12
1.43
45.23
1.40

NonHispanic
white

Black

Hispanic

Other/un
known

Readmission
rates

81.99
13.35
81.72
13.40
81.26
13.54
80.82
13.66
80.46
13.69
80.19
13.66
79.96
13.60
79.93
13.45
79.85
13.28
79.56
13.29
79.57
13.12

9.38
8.90
9.38
8.92
9.57
9.08
9.76
9.23
9.86
9.29
9.86
9.28
9.84
9.21
9.71
9.15
9.56
9.08
9.47
9.02
9.28
8.95

5.50
9.17
5.61
9.24
5.74
9.36
5.85
9.44
5.93
9.51
5.94
9.52
5.93
9.52
5.84
9.41
5.80
9.22
5.87
9.24
5.71
8.90

3.13
4.97
3.29
5.01
3.43
5.02
3.57
5.04
3.75
5.02
4.00
5.04
4.27
5.04
4.52
5.02
4.78
5.01
5.10
5.06
5.45
5.16

18.20
2.19
84.07
13.97
83.66
14.10
83.27
14.20
82.90
14.23
82.59
14.20
82.28
14.13
82.07
13.99
81.89
13.83
81.63
13.83
81.59
13.67
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Assumption Testing
To determine the appropriate analyses, I conducted tests to examine whether
specific assumptions were met for normality, homoscedasticity, and linearity. To test the
normality assumption, I plotted the distribution of residuals. The figure revealed a normal
distribution of residuals, suggesting this assumption was not violated (Figure 1). Two
additional measures of normality, Skewness and Kurtosis, were also not violated (p = .35
and p = .81, respectively). I used a different test to examine whether the variability of the
variable was unequal across the range of values of a second variable that predicts it,
which revealed that the homoscedasticity assumption was not violated (p = .75). To test
the linearity assumption, I plotted the residuals against the dependent variable in the
model (i.e., readmission rates after hospitalization). The residuals for each of the
predictor variables matched the dependent variable in a linear pattern, suggesting
linearity was not violated (Figure 2). Given that the linearity assumption was not
violated, linear regression analyses were used to test the hypotheses.
Regression Results
I conducted several regression analyses to address the research questions. I
conducted one regression using row-wise averages from 2007 to 2017 for each variable
and separate regression analyses for each year. I included gender and race/ethnicity as
predictor variables in the model and included readmission rates after hospitalization as an
outcome variable to test the hypotheses. To test whether there were any significant
interactions between gender, race/ethnicity, I included the interaction terms of gender and
race/ethnicity as a predictor in the model.
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Research Question 1. The first research question was: To what extent, if at all,
does patient gender predict 30-day hospital readmission rate for ESRD patients in the
United States? The results of the linear regression for RQ1 is presented in Table 2. The
results of the regression analysis using row-wise averages from years 2007 to 2017, for
each variable of interest, revealed three main effects: the percentage of females (  =1.02,
p < .01) Blacks ( = .08, p < .01), and Hispanics ( = .05, p < .05) in the population, all
significantly predicted readmission rates after hospitalization. The model was overall
significant, 𝑅2 = .35, CI [.26, .42], and accounted for 35% of the variance.
The specific regression results to address RQ1 revealed that the percentage of
females in the population significantly predicted readmission rates after hospitalization ( 
= 1.02, p < .01). Specifically, higher percentages of females in the population were
associated with higher readmission rates after hospitalization. Furthermore, looking at the
relationship between gender and readmission rates after hospitalization revealed that in
every year until 2015, the percentage of females significantly and positively predicted
readmission rates. Based on these results, H01 can be rejected, as gender does predict
readmission rates.
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Table 2
Regression Results Using Row-Wise From Years 2007 to 2017, for Each Variable and
Hospital Readmission Rates as the Criterion

Predictor

b

b
95% CI
[LL, UL]

(Intercept)

-38.67

[-77.53,
0.19]

Interaction

-0.01

[-0.02, 0.00]

-2.97

[0.30, 1.73]

-2.97

[-0.01, 0.90]

-2.97

beta

Female

1.02**

White

0.45

Black

0.08**

[0.04, 0.13]

-2.97

Hispanic

0.05*

[0.00, 0.09]

-2.97

beta
95% CI
[LL, UL]

Fit

[-6.02,
0.08]
[-6.02,
0.08]
[-6.02,
0.08]
[-6.02,
0.08]
[-6.02,
0.08]
R2 = .353**
95% CI[.26,.42]

Note. * indicates p < .05; ** indicates p < .01. A significant b-weight indicates the beta-weight and semipartial correlation are also significant. b represents unstandardized regression weights; beta indicates the
standardized regression weights; sr2 represents the semi-partial correlation squared; r represents the zeroorder correlation. LL and UL indicate the lower and upper limits of a confidence interval, respectively.

Research Question 2. The second research question was: To what extent, if at all,
does patient race/ethnicity predict 30-day hospital readmission rate for ESRD patients in
the United States? I conducted regression analyses using row-wise averages from the
years 2007 to 2017 to answer this question. The results of the linear regression for RQ2
are presented in Table 3. These analyses revealed that the percentage of Blacks and
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Hispanics in the population both significantly predicted readmission rates after
hospitalization ( = .08, p < .01 and  = .05, p < .05, respectively). Specifically, higher
percentages of Blacks and Hispanics in the population were associated with higher 30day hospital readmission rate for ESRD patients in the United States. The percentage of
Whites in the population was not associated with hospital readmission rates, CI [-0.01,
0.90].
Additionally, I ran separate regression analyses for each year from 2007 to 2017,
with race/ethnicity as a predictor in the model and readmission rates after hospitalization
as an outcome variable. In 2007, the percentage of Blacks and the percentage of Whites
were significant predictors of readmission rates after hospitalization. The percentage of
Hispanics significantly and positively predicted readmission rates in 2008 and from 2014
to 2017. The percentage of Whites only positively predicted readmission rates in 2007
and 2008.
Furthermore, looking at the relationship between race and readmission rates after
hospitalization revealed that every year until 2015, the percentage of Blacks significantly
and positively predicted readmission rates. The full regression results for each year for
RQ2 can be found in Table 3. Based on these results, H02 can be rejected, as
race/ethnicity does predict readmission rates.
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Table 3
2008-2017 Regression Analyses of Hypothesized Predictors of Hospital Readmission
Rates
Year

Predictor

2008

Female
White
Interaction
Black
Hispanic

b

1.09**
0.48*
-0.01*
0.08**
0.05*

b
95% CI

[0.37, 1.82]
[0.03, 0.94]
[-0.02, 0.00]
[0.03, 0.13]
[0.00, 0.10]

r

Fit

.37**
-.42**

.49**
.16**
R2 = .349**
95% CI[.26,.42]

2009

Female
White
Interaction
Black
Hispanic

1.10**
0.47
-0.01*
0.08**
0.05

[0.35, 1.85]
[-0.00, 0.94]
[-0.02, 0.00]
[0.02, 0.13]
[-0.01, 0.10]

.38**
-.42**

.48**
.16**
R2 = .341**
95% CI[.25,.41]

2010

Female
White
Interaction
Black
Hispanic

0.99*
0.41
-0.01
0.07**
0.04

[0.21, 1.76]
[-0.08, 0.89]
[-0.02, 0.00]
[0.02, 0.13]
[-0.01, 0.09]

.37**
-.41**
.47**
.16**
R2= .318**
95% CI[.23,.38]

2011

Female
White
Interaction
Black
Hispanic

0.91*
0.39
-0.01
0.09**
0.04

[0.13, 1.70]
[-0.10, 0.89]
[-0.02, 0.00]
[0.04, 0.14]
[-0.01, 0.09]

.36**
-.39**
.48**
.12*
R2 = .308**
95% CI[.22,.38]

2012

Female
White
Interaction
Black

0.81*
0.30
-0.01
0.08**

[0.06, 1.55]
[-0.17, 0.78]
[-0.01, 0.00]
[0.03, 0.12]

.38**
-.41**
.48**
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Year

Predictor

b

b
95% CI

Hispanic

0.03

[-0.02, 0.08]

r

Fit

.14*
R2 = .320**
95% CI[.23,.39]

2013

Female
White
Interaction
Black
Hispanic

0.92*
0.41
-0.01
0.08**
0.04

[0.22, 1.63]
[-0.04, 0.87]
[-0.02, 0.00]
[0.04, 0.13]
[-0.00, 0.09]

.37**
-.42**
.50**
.14*
R2 = .336**
95% CI[.24,.40]

2014

Female
White
Interaction
Black
Hispanic

0.86*
0.39
-0.01
0.10**
0.05*

[0.11, 1.61]
[-0.09, 0.88]
[-0.02, 0.00]
[0.05, 0.15]
[0.01, 0.10]

.36**
-.40**
.50**
.13*
R2 = .322**
95% CI[.23,.39]

2015

Female
White
Interaction
Black
Hispanic

0.74
0.33
-0.01
0.10**
0.06**

[-0.01, 1.49]
[-0.16, 0.82]
[-0.01, 0.00]
[0.05, 0.14]
[0.02, 0.11]

.34**
-.39**
.46**
.15**
R2 = .289**
95% CI[.20,.36]

2016

Female
White
Interaction
Black
Hispanic

0.73
0.32
-0.01
0.09**
0.06*

[-0.04, 1.51]
[-0.19, 0.82]
[-0.02, 0.00]
[0.05, 0.14]
[0.01, 0.10]

.35**
-.40**
.46**
.16**
R2 = .287**
95% CI[.20,.35]

2017

Female
White
Interaction
Black
Hispanic

0.53
0.18
-0.00
0.10**
0.07**

[-0.23, 1.29]
[-0.33, 0.68]
[-0.01, 0.01]
[0.06, 0.14]
[0.03, 0.12]

.35**
-.42**
.46**
.19**
R2 = .310**
95% CI[.22,.38]

Note. * indicates p < .05; ** indicates p < .01. A significant b-weight indicates the beta-weight
and semi-partial correlation are also significant. b represents unstandardized regression weights;
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beta indicates the standardized regression weights; sr2 represents the semi-partial correlation
squared; r represents the zero-order correlation. LL and UL indicate the lower and upper limits of
a confidence interval, respectively.

Research Question 3. The third research question was: Are there any significant
interaction impact between gender and race/ethnicity in predicting 30-day hospital
readmission rate for ESRD patients in the United States? To test whether there are any
significant interactions between gender and race/ethnicity, I conducted regression
analyses were conducted with the interaction between gender and race/ethnicity as a
predictor in the model. This interaction was significant,  = -.01, p < .05. The interaction
was such that at lower levels of females in the population, levels of Whites in the
population have no significant relationship with hospital readmission rates. However, at
higher levels of females in the population, fewer (vs. more) Whites in the population are
associated with higher hospital readmission rates. The interaction between race and
gender was only significant in 2007, 2008, and 2009. The full regression results can be
found in Table 4. The regression results for the interaction between gender and
race/ethnicity in predicting readmission rates for years 2008-2017 can be found in Table
4. Based on these results, null hypothesis H03 can be rejected, as there was a significant
interaction between the percentage of females in the population and the percentage of
Whites in the population, with regards to hospital readmission rates.
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Table 4
2007 Regression Results Using Hospital Readmission Rate as the Criterion

Predictor
(Intercept)
Female
White
Interaction
Black
Hispanic

b
-45.34*
1.16**
0.51*
-0.01*
0.07**
0.05

b
95% CI
[LL, UL]
[-83.75, -6.92]
[0.45, 1.86]
[0.07, 0.95]
[-0.02, -0.00]
[0.02, 0.12]
[-0.00, 0.09]

beta

0.91
0.91
0.91
0.91
0.91

beta
95% CI
[LL, UL]

Fit

[0.36, 1.46]
[0.36, 1.46]
[0.36, 1.46]
[0.36, 1.46]
[0.36, 1.46]
R2 = .354**
95%
CI[.26,.42]

Note. * indicates p < .05; ** indicates p < .01. A significant b-weight indicates the beta-weight and semipartial correlation are also significant. b represents unstandardized regression weights; beta indicates the
standardized regression weights; sr2 represents the semi-partial correlation squared; r represents the zeroorder correlation. LL and UL indicate the lower and upper limits of a confidence interval, respectively.

Summary
Section 3 presented the results of the quantitative analysis to test the different
research questions of the study. The study outcomes can be found in tables and graphs
with descriptive narratives. I used SPSS for the data analysis. The first information
presented included in the result section is for the descriptive statistics summaries of the
study variables. Then, parametric assumption testing results, including normality,
homoscedasticity, and linearity were discussed. This analysis was followed by the
discussion of the results of the different regression analyses to address the three different
research questions of this study. This chapter ended with a summary of the results.
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Taken together, the results of the different regression analyses have several
implications for the posed research questions. For RQ1, the regression analysis results
resulted in the rejection of H01, as gender (i.e., the percentage of females in the
population) was a significant predictor of hospital readmission rates every year until
2015.
For RQ2, the regression analysis results resulted in the rejection of H02, as
race/ethnicity was a significant positive predictor of hospital readmission rates.
Specifically, the percentage of Blacks significantly and positively predicted hospital
readmission rates almost every year. The percentage of Hispanics significantly and
positively predicted readmission rates in 2008 and from 2014-2017. The percentage of
Whites only positively predicted readmission rates in 2007 and 2008.
For RQ3, results of the regression analysis resulted to the partial rejection of H03
because the interaction between race and gender was significant in 2007, 2008, and 2009.
Specifically, the interaction impact showed that at lower levels of females in the
population, levels of Whites in the population have no significant relationship with
hospital readmission rates. However, at higher levels of females in the population, fewer
(vs. more) Whites in the population are associated with higher hospital readmission rates.
The following section, Section 4 concludes this study. Implications of the results
of the data analysis were discussed in detail in Section 4. Suggestions on how the
findings may be applied in an organizational setting and a summary of recommendations
for future research are also discussed in Section 4.
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Section 4: Application to Professional Practice and Implications for Social Change
Introduction
ESRD is a severe issue in the medical field today. ESRD affects over two million
people globally (Robinson et al., 2016). One type of treatment for ESRD is hemodialysis,
an external filtration device that cleanses the patient’s blood instead of the kidney doing
so. The primary remedy for ERSD is a kidney transplant, but a donor kidney is difficult
to obtain as there is often a lack of supply to meet the demand, and therefore, the
problems associated with ESRD lead to frequent emergency department visits and
hospital readmissions (Robinson et al., 2016). ESRD patients must contend with other
issues such as socioeconomic and demographic differences. A major concern is racism,
particularly for Black people, which various studies have shown predict worse than
average ESRD outcomes, indicating that a psychosocial element may be associated with
treatment (Savage, 2017). The purpose of this quantitative nonexperimental, historical,
correlational design was to determine the extent to which gender and race/ethnicity
predict 30-day readmission rates after hospitalization for ESRD patients. This section will
look at the interpretation of the findings as they relate to the literature, limitations,
recommendations, and implications for social change. It will close with a conclusion.
Theoretical Foundation
I selected a theoretical foundation to guide and contextualize this research. This
framework was a theory of the determinants of avoidable readmissions in ESRD by
Matthew et al. (2015). The theory illustrates the characteristics that cause preventable
hospital readmissions for the disease. These characteristics can be length of hospital stay,

72
quality of the hospital, its dialysis facility, the doctors and care providers, and how the
treatment is paid for. However, this study only included one aspect of the theory. This
aspect was the role of patient characteristics. As the innumerable factors that cause
avoidable readmission are interconnected, it is important to understand the relationship
between variables (Matthew et al., 2015). Through the focus on demographic and
socioeconomic variables, hospitals may be provided with increased resources to mitigate
this problem, thereby allowing this theory to expand.
Interpretation of the Data
I used regression analysis to understand the relationships between the variables
and readmission rates of ESRD patients (see Gallo, 2015; Montgomery et al., 2012). The
study results are as follows: I rejected the null hypothesis of RQ1 and found that gender,
in this case the percentage of females, was a significant predictor of hospital readmission
rates in every year into 2015. I also rejected the null hypothesis for RQ2 as race/ethnicity
was found to have a significant positive predictor of hospital readmission rates. Of the
races, Blacks have the highest readmission rate, with Hispanics also maintaining high
rates. Lastly, I rejected the null hypothesis of RQ3 as there was zero correspondence
between race and gender in the years 2007, 2008, and 2009.
Interpretation of the Findings
Research Question 1
The first research question asked to what extent, if at all, a patient’s gender
predicts 30-day hospital readmission rate for ESRD patients in the United States. After
regression analysis, the study found a statistically significant relationship between
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females in the population and readmission rates after hospitalization, thereby rejecting the
null hypothesis. More specifically, males are much less likely to have high readmission
rates when compared to females in every year until 2015. Thus, there was a statistically
significant relationship between gender and readmission rates after hospitalization.
The results of the relationship between gender and readmission rates are difficult
to dispute as the sample of 77 Medicare patients came from archived sources. A random
assignment was not applied because of the need to select the chosen demographic
variables. Regression analysis was the strongest analysis approach to determine the
relationship between gender and readmission rates due to the targeted sample (see Gallo,
2015; Montgomery et al., 2012).
In a study by Chan et al. (2017), the authors examined predictors for 30-day
readmission rates for ESRD and found gender to be a significant independent predictor.
This is supported in a separate study by Chan (2017), which found that age, female
gender, and comorbidities all influence 30-day readmission rates. Neugarten and
Reckelhoff (2015) studied kidney disease across various animals and found that ESRD
progressed more quickly in males than females. The authors suggested that sex hormones
rather than the physical structure of genders predicted differences with the disease.
However, the suggestion that it is sex hormones rather than gender itself goes against this
study's results as the results indicated a statistically significant relationship between the
ESRD readmission rates and gender. This is not to discount Neugarten and Reckelhoff
(2015), but their study results focused on animals rather than humans.

74
This study aligned with the theoretical framework of Matthew et al. (2015), which
highlighted that patient characteristics represent an important factor in ESRD. Matthew et
al. suggested that by studying single demographics, there could be increased knowledge
of the broader issues of the disease. This was certainly the case with RQ1, as it showed
that women had higher rates than men, yet remained underserved in terms of treatment.
These results could help reduce avoidable readmissions due to a lack of treatment from a
healthcare provider.
Research Question 2
The second research question asked to what extent, if at all, a patient’s
race/ethnicity predicts 30-day hospital readmission rate for ESRD patients in the United
States. The study found a significant relationship between readmission rates and
ethnicity, specifically among Black and Hispanic patients. Black individuals, however,
had the highest rate of ESRD, with Hispanics coming in second, yet both were much
more significant when compared to Whites.
In general, diseases such as diabetes and hypertension differ among varying
ethnic groups (Webster et al., 2017). This information can also be applied to ESRD and
other related factors. Lovasik et al. (2016) noted that not only does race predict ESRD
outcomes, but it can also affect other predictors. An example of this would be a dietary
acid load, which can predict the development of kidney disease and its progression
among different races and ethnicities, in this case, Whites and Blacks (Crews et al.,
2018). Crews et al. (2018) pointed out that through the various stages of renal disease
among racial groups, Black people had a disadvantage with higher rates.
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As noted earlier, race can be linked to different socioeconomic conditions. In a
study by Nee et al. (2017), the authors noted that care availability differs by
demographics. Patients who have easy access to nephrology before reaching ESRD had
lower mortality and morbidity rates (Gillespie et al., 2015). Therefore, those of different
races need to receive the same treatment as those in other socioeconomic groups. Nee et
al. (2017) studied a sample of 739,537 patients from 2007-2012 and found that those in
poverty who have Medicare and Medicaid eligibility were less likely to undergo preESRD nephrological care, especially Blacks and Hispanics when compared to Whites.
Therefore, Gillespie et al. (2015) noted that this put impoverished and racial minorities at
a greater risk for ESRD mortality than Whites. This risk can also affect employment
status and insurance availability. Cervantes et al. (2018) noted that those with access to
dialysis regularly could decrease the risk of mortality up to 14 times compared to
emergency access later.
Newman et al. (2016) examined racial differences in the hospitalization of
patients who wait on kidney transplants. The study had a sample of 24,582 patients
between 2005 and 2009. The results found that hospitalized patients were less likely to
receive a kidney transplant, and, unfortunately, Blacks and Hispanics had higher rates of
hospitalization than Whites. The higher rate of hospitalization creates an uneven playing
field for those who need kidney transplants.
However, not all differences regarding race and ethnicity can be placed squarely
on treatment. Savage (2017) found that Black ESRD patients were less likely to adhere to
treatment guidelines than other races and ethnicities. One reason for this might be
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perceived racism in the healthcare system, as participants stated that they felt everyday
racism with the medical community. This everyday racism diminishes the participants’
willingness to adhere to guidelines for ESRD treatment. When coupled with the
likelihood of increased chances of ESRD and reduced healthcare access, this creates a
negative incentive to receiving and maintaining positive treatment.
Like RQ1, the theoretical framework was relevant to this result as race can affect
ESRD treatment. These broader principles can reveal discrepancies such as differences in
healthcare access among varying demographics and socioeconomic statuses. This affects
the way that healthcare is received (Newman et al., 2016). Webster et al. (2017) pointed
out that differences among groups can influence ESRD through differing contexts.
Typically, avoidable readmissions can be reduced through treatment; however, when
there is a failure of the healthcare provider or self-care, treatment can be worsened.
Therefore, Matthew et al.’s (2015) framework holds that the narrow results may link to
broader issues.
Research Question 3
RQ3 asks if there is a significant interaction between gender and race/ethnicity in
predicting 30-day hospital readmission rate for ESRD patients in the United States. Using
regression analysis, I focused on gender and race/ethnicity as predictors in the model.
There was found to be a significant relationship between both variables; however, there
were some inconsistencies. At lower levels of females in the population, levels of whites
had no relationship with hospital readmission. However, more females versus more
Whites were associated with higher hospitalization rates. The interaction between race
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and gender only occurred in 2007, 2008, and 2009. Nevertheless, these results were
enough to reject the null hypothesis.
The results of this research question were not surprising. As RQ1 through RQ3
were all found to have statistically significant relationships, it would be shocking to find
no correlation between the variables. Additionally, the literature review agreed with the
previous research questions, thus further validating the results.
For example, Patzer et al. (2015) found that impoverished patients are less likely
to be referred for kidney transplants. Additionally, Nee et al. (2017) found that those in
poverty are less likely to have pre-ESRD nephrology than those with money and that
those in poverty, as measured by Medicare and Medicaid eligibility, were less likely to
receive care as regards to race for Blacks and Hispanics relative to Whites. Gillespie et al.
(2015) summed this up in their study that showed impoverished and racial minorities are
at risk for 1st-year mortality. Lastly, Shah et al. (2018) found that women are 6% less
likely to be given information about kidney transplants than men. Therefore, the
combination of these studies reinforces the results of the RQ3. Most importantly, the
results of the RQ3 strengthen the theoretical framework. Each response to the research
question showed that smaller individual variables could reflect broader issues when
regarding ESRD. Each one of these variables provides further opportunity for future
research.
Limitations
This study had numerous limitations. The first limitation was that the data was
secondary. No data was gathered by me, meaning that I had no control over the data
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collection process and how precise it was. This process left me to assume that the data
was accurate while potentially leaving the door open for possible data errors that cannot
be predicted. The second limitation also regarded data. Although there is a large sample
size that offered strong external validity, the gathered data was only for Medicare and
Medicaid patients. The use of only Medicare and Medicaid patients limits the
generalization of the results to the full population. The third limitation was that only
public data sets were utilized in the study. Private data sets may offer different outcomes,
especially regarding race and gender. The final limitation was that the final research
question did not explain why disparities may exist between gender and race/ethnicity.
While there was a significant relationship between the variables, it only occurred during
certain years. Without further research, it is unknown why these years were more
important than others.
One issue with the research's internal validity was that there was an inability to
create patient inferences due to the nonexperimental approach. The variables of interest
are measured and unmanipulated, leaving the research correlational and the associations
between the variables uninfluenced. Additionally, the use of real historical hospital data
did increase the reliability and external validity of the investigation, as it makes it easier
to generalize the results to other patients. However, due to the study's historical
timeframe, the reliability and external validity were limited only to the time selected.
Recommendations
This study's results have yielded recommendations that I propose for future
research, practical recommendations that could be used to improve health outcomes, and
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implications for social change. Much like the theoretical framework suggested,
concentrating on smaller aspects of ESRD patients can provide insight into the bigger
picture. The new emphasis on gender, race, and socioeconomic status during diagnosis
and treatment can reduce complications. Blacks and Hispanic patients and those with
reduced resources should be provided with the appropriate knowledge and treatment from
the beginning of the diagnosis. A renewed emphasis on studying these demographics
could provide further insight into the phenomenon. Further research could focus on how
these demographics are treated and what information is given to them throughout their
medical diagnosis and treatment. Issues regarding race can further be broken down to
better understand how differences affect patients throughout the treatment process. Also,
socioeconomic conditions mixed with geographic locations could provide a better
understanding of how a lack of resources and availability affects ESRD patients.
Other recommendations for future research would be to replicate the current
study, but include more data sets, both publicly available and those created for an
individual focus. The result of a study like this could help contribute to the external
validity of this study. Data can also come from various countries to help determine the
effectiveness of treatment within the United States. Additionally, variables such as
education and age can be used to understand the phenomenon further. Like the theoretical
framework stated, focusing on smaller subsets can provide greater insight. Finally, a
change in research design, such as quantitative to qualitative, can provide greater
information. Understanding the process from the doctors' or patients' point of view can
help understand the deficits within the treatment process.
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A shift to a qualitative study could also explore ESRD. Understanding the
patients’ and doctors’ points of view could shed light on the phenomenon in ways a
quantitative methodology just could not. For instance, it would be interesting to compare
demographics in relation to the care that they receive. This would provide first hand
knowledge of any discrepancies of treatment between races. Another study could
qualitatively explore what knowledge and education the patients receive post discharge.
Doing so, may indicate ways in which ESRD education can be improved.
Implications for Positive Social Change
This study yielded a variety of options for positive social change. Primarily
doctors and healthcare providers can place a much-needed emphasis on these highlighted
groups which can now be diagnosed and treated with the appropriate amount of attention.
By treating these patients early and often, there could be a less financial burden on the
patients and institutions and an increased lifespan in early access to get on a kidney
transplant list. An increased lifespan strengthens families and reduces patient stress.
A renewed focus on providing appropriate treatment, knowledge and literature can also
help mitigate readmission rates. Knowing that women have a higher readmission rate
allows doctors and specialists to place more emphasis on ESRD during the patient’s
initial visits. More emphasis could be placed on preventative measures and early
treatment, such as dialysis, to help reduce readmission rates. Additionally, it would
behoove both the doctor and the patient to screen early and often for ESRD, especially as
they get older. Women could also be made more aware of the likelihood that they could
be diagnosed with ESRD. Patients could be educated on high blood pressure, diabetes
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and other diseases which may relate to ESRD. Literature, such as pamphlets, can be
distributed early and often highlights the importance and dire consequences of the
disease. This knowledge could then be used for preventative measures to help mitigate
and reduce the likelihood of contraction. Women are up against barriers that prevent them
from receiving the same treatment and knowledge as men. By focusing in the future on
women’s treatment, this discrepancy can be rectified. Women could be given more
knowledge and access, thereby reducing mortality rates.
Conclusion
The purpose of this quantitative nonexperimental historical, correlational design
was to determine the extent to which gender and race/ethnicity predict 30-day
readmission rates after hospitalization for ESRD patients. The study also examined
interactions between these predictors on the overall risk of ESRD-related hospitalization.
The study found that gender and race can all be predictors of ESRD hospitalization and
therefore readmissions. Future research should further expand the data to understand
other variables, and practical implications should focus on giving these groups the
treatment of knowledge they need as early as possible.
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